Explanation
This regulatory network was inferred from the input dataset. The miRNAs and mRNAs are
presented as round and rectangle nodes respectively. The numerical value popped up upon mouse over the gene node is the log2 transformed fold-change of the gene expression between the two groups. All of the nodes are clickable, and the detailed information of the miRNAs/mRNAs and related cancer pathway will be displayed in another window. The edges between nodes are supported by both interactions (predicted or experimentally verified) and correlations learnt from cancer dataset. The numerical value popped up upon mouse over the edge is the correlation beat value (effect size) between the two nodes. The experimental evidences of the edges reported in previous cancer studies are highlighted by red/orange color. All of these information can be accessed by the "mouse-over" action. This network shows a full map of the miRNA-mRNA regulation of the input gene list(s), and the hub miRNAs (with the high network degree/betweenness centrality) would be the potential cancer drivers or tumor suppressors. The full result table can be accessed in the "Regulations" tab.
"miRNACancerMAP" is also a network visualization tool for users to draw their regulatory network by personal customization. Users can set the complexity of the network by limiting the number of nodes or edges. And the color of the nodes can be defined by different categories of the mRNAs and miRNAs, such as Gene-Ontology, pathway, and expression status. Users can also select to use network degree or network betweenness centrality to define the node size. And edges can be black or colored by the correlation. Purple edge means negative correlation (mostly found between miRNA and mRNA), and blue edge means positive correlation (found in PPI or miRNA-miRNA sponge effect). We can also add the protein-protein interactions (PPI) into the network. This result will show the cluster of genes regulated by some specific miRNAs. Additionally, miRNA-miRNA edges can be added by the "miRNA sponge" button, presenting some clusters of miRNAs that have the interactions via sponge effect.
miRNA-gene regulations
| Num | microRNA | Gene | miRNA log2FC | miRNA pvalue | Gene log2FC | Gene pvalue | Interaction | Correlation beta | Correlation P-value | PMID | Reported in cancer studies |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | hsa-miR-106b-5p | APC | 0.65 | 0 | -0.18 | 0.06792 | miRNAWalker2 validate; miRTarBase | -0.15 | 0.00024 | 23087084 | miR 106b downregulates adenomatous polyposis coli and promotes cell proliferation in human hepatocellular carcinoma; Moreover we demonstrated that miR-106b downregulates APC expression by directly targeting the 3'-untranslated region of APC messenger RNA; Taken together our results suggest that miR-106b plays an important role in promoting the proliferation of human hepatoma cells and presents a novel mechanism of micro RNA-mediated direct suppression of APC expression in cancer cells |
| 2 | hsa-miR-21-5p | APC | 1.51 | 0 | -0.18 | 0.06792 | miRNAWalker2 validate | -0.17 | 0 | 23773491; 24832083 | The prognostic significance of APC gene mutation and miR 21 expression in advanced stage colorectal cancer; The aim of this study was to analyse the association of APC gene mutation and miR-21 expression with clinical outcome in CRC patients; APC gene mutation and expression of APC and miR-21 were analysed by direct DNA sequencing and real-time reverse transcription polymerase chain reaction; APC gene expression was low in CRC and negatively correlated with miR-21 expression and gene mutation; In Taiwan downregulation of the APC gene in CRC correlated with gene mutation and miR-21 upregulation; APC mutation and miR-21 expression could be used to predict the clinical outcome of CRC especially in patients with advanced disease;MicroRNA 21 promotes tumour malignancy via increased nuclear translocation of β catenin and predicts poor outcome in APC mutated but not in APC wild type colorectal cancer; However in our preliminary data the prognostic value of miR-21 levels was observed only in adenomatous polyposis coli APC-mutated tumours not in APC-wild-type tumours; We enrolled 165 colorectal tumour to determine APC mutation miR-21 levels and nuclear β-catenin expression by direct sequencing real-time PCR and immunohistochemistry |
| 3 | hsa-miR-103a-3p | ARHGAP5 | 0.77 | 0 | -0.39 | 8.0E-5 | MirTarget | -0.19 | 1.0E-5 | NA | |
| 4 | hsa-miR-155-5p | ARHGAP5 | 0.01 | 0.95651 | -0.39 | 8.0E-5 | mirMAP | -0.11 | 1.0E-5 | NA | |
| 5 | hsa-miR-15a-5p | ARHGAP5 | 0.35 | 0.00077 | -0.39 | 8.0E-5 | MirTarget; miRNATAP | -0.14 | 0.00276 | NA | |
| 6 | hsa-miR-16-1-3p | ARHGAP5 | 0.39 | 0.00112 | -0.39 | 8.0E-5 | MirTarget | -0.11 | 0.00823 | NA | |
| 7 | hsa-miR-17-5p | ARHGAP5 | 0.7 | 2.0E-5 | -0.39 | 8.0E-5 | miRNAWalker2 validate | -0.17 | 0 | NA | |
| 8 | hsa-miR-181a-5p | ARHGAP5 | 0.25 | 0.05519 | -0.39 | 8.0E-5 | mirMAP | -0.18 | 0 | NA | |
| 9 | hsa-miR-181b-5p | ARHGAP5 | 0.49 | 0.00105 | -0.39 | 8.0E-5 | mirMAP | -0.16 | 0 | NA | |
| 10 | hsa-miR-18a-5p | ARHGAP5 | 0.92 | 2.0E-5 | -0.39 | 8.0E-5 | MirTarget | -0.14 | 0 | NA | |
| 11 | hsa-miR-19a-3p | ARHGAP5 | 1.02 | 0 | -0.39 | 8.0E-5 | miRNATAP | -0.1 | 2.0E-5 | NA | |
| 12 | hsa-miR-19b-3p | ARHGAP5 | 0.6 | 0.00017 | -0.39 | 8.0E-5 | miRNATAP | -0.13 | 3.0E-5 | NA | |
| 13 | hsa-miR-421 | ARHGAP5 | 0.94 | 0 | -0.39 | 8.0E-5 | PITA; miRanda; mirMAP; miRNATAP | -0.1 | 0.00026 | NA | |
| 14 | hsa-miR-500a-5p | ARHGAP5 | 0.8 | 0 | -0.39 | 8.0E-5 | mirMAP | -0.13 | 4.0E-5 | NA | |
| 15 | hsa-miR-501-5p | ARHGAP5 | 1.15 | 0 | -0.39 | 8.0E-5 | PITA; mirMAP | -0.14 | 0 | NA | |
| 16 | hsa-miR-590-5p | ARHGAP5 | -0.1 | 0.31003 | -0.39 | 8.0E-5 | miRanda | -0.13 | 0.00897 | NA | |
| 17 | hsa-let-7b-3p | AXIN2 | -1.22 | 0 | 0.11 | 0.75298 | miRNATAP | -0.27 | 0.0205 | NA | |
| 18 | hsa-let-7g-3p | AXIN2 | -1.14 | 0 | 0.11 | 0.75298 | MirTarget | -0.33 | 0.01126 | NA | |
| 19 | hsa-miR-15b-5p | AXIN2 | 0.23 | 0.08248 | 0.11 | 0.75298 | miRTarBase; MirTarget; miRNATAP | -0.45 | 0.00081 | NA | |
| 20 | hsa-miR-16-2-3p | AXIN2 | -0.03 | 0.80516 | 0.11 | 0.75298 | mirMAP | -0.64 | 0 | NA | |
| 21 | hsa-miR-16-5p | AXIN2 | -0.4 | 0.0001 | 0.11 | 0.75298 | miRNAWalker2 validate; miRTarBase; MirTarget; miRNATAP | -0.49 | 0.00421 | NA | |
| 22 | hsa-miR-195-3p | AXIN2 | -1.09 | 0 | 0.11 | 0.75298 | mirMAP | -0.31 | 0.00083 | NA | |
| 23 | hsa-miR-195-5p | AXIN2 | -1.86 | 0 | 0.11 | 0.75298 | MirTarget; miRNATAP | -0.25 | 0.00506 | NA | |
| 24 | hsa-miR-26b-3p | AXIN2 | -1.26 | 0 | 0.11 | 0.75298 | MirTarget | -0.59 | 3.0E-5 | NA | |
| 25 | hsa-miR-326 | AXIN2 | -1.88 | 0 | 0.11 | 0.75298 | miRanda | -0.36 | 2.0E-5 | NA | |
| 26 | hsa-miR-338-5p | AXIN2 | -0.22 | 0.25239 | 0.11 | 0.75298 | miRNATAP | -0.34 | 0.00017 | NA | |
| 27 | hsa-miR-424-5p | AXIN2 | -2.63 | 0 | 0.11 | 0.75298 | MirTarget; miRNATAP | -0.19 | 0.03018 | NA | |
| 28 | hsa-miR-497-5p | AXIN2 | -1.41 | 0 | 0.11 | 0.75298 | MirTarget; miRNATAP | -0.29 | 0.00329 | NA | |
| 29 | hsa-miR-616-3p | AXIN2 | -0.7 | 2.0E-5 | 0.11 | 0.75298 | MirTarget | -0.42 | 8.0E-5 | NA | |
| 30 | hsa-let-7b-5p | BIRC5 | -0.96 | 0 | 4.5 | 0 | miRNAWalker2 validate | -0.71 | 0 | NA | |
| 31 | hsa-miR-101-3p | BIRC5 | -1.48 | 0 | 4.5 | 0 | miRNAWalker2 validate | -1.33 | 0 | NA | |
| 32 | hsa-miR-10a-5p | BIRC5 | -1.48 | 0 | 4.5 | 0 | miRNAWalker2 validate | -0.71 | 0 | NA | |
| 33 | hsa-miR-203a-3p | BIRC5 | -1.34 | 9.0E-5 | 4.5 | 0 | miRTarBase | -0.13 | 0.00935 | 22713668; 27714672 | Luciferase assays were also performed to validate BIRC5 and LASP1 as miR-203 targets; Both miR-203 and BIRC5 siRNA signicantly inhibited cell proliferation in TNBC cells; Moreover up-regulated of BIRC5 and LASP1 was able to abrogate the effects induced by transfection with the miR-203 precursor;miR 203 is a predictive biomarker for colorectal cancer and its expression is associated with BIRC5; The purpose of this study was to explore the role of miR-203 in colorectal cancer CRC and evaluate the correlation between miR-203 and BIRC5; Finally miR-203 expression was negatively associated with that of BIRC5 r = -0.8150 P < 0.05 |
| 34 | hsa-miR-218-5p | BIRC5 | -0.5 | 0.03986 | 4.5 | 0 | miRTarBase; MirTarget | -0.14 | 0.03933 | 25473903; 25900794; 26442524 | Survivin BIRC5 was subsequently identified as an important cervical cancer target of miR-218 using in silico prediction mRNA profiling and quantitative real-time PCR qRT-PCR;miR-218 binds survivin BIRC5 mRNA 3'-UTR and down-regulated reporter luciferase activity;MiR-218 promoted apoptosis inhibited cell proliferation and caused cell cycle arrest in CRC cells by suppressing BIRC5 expression; In conclusion we demonstrated that high miR-218 expression had a positive prognostic value in 5-FU-based treatments for CRC patients and discovered a novel mechanism mediated by miR-218 to promote apoptosis and to function synergistically with 5-FU to promote chemosensitivity by suppressing BIRC5 and TS in CRC |
| 35 | hsa-miR-30c-5p | BIRC5 | -0.43 | 0.00016 | 4.5 | 0 | miRNAWalker2 validate | -0.45 | 0.00191 | NA | |
| 36 | hsa-miR-335-5p | BIRC5 | -1.61 | 0 | 4.5 | 0 | miRNAWalker2 validate; MirTarget | -0.5 | 0 | 23232114 | Genetic variation in a miR 335 binding site in BIRC5 alters susceptibility to lung cancer in Chinese Han populations; In support of the postulation that the 3' UTR SNP may directly affect miRNA-binding site reporter gene assays indicated BIRC5 was a direct target of miR-335 and the rs2239680 T>C change resulted in altered regulation of BIRC5 expression; Our findings defined a 3' UTR SNP in human BIRC5 oncogene that may increase individual susceptibility to lung cancer probably by attenuating the interaction between miR-335 and BIRC5 |
| 37 | hsa-miR-542-3p | BIRC5 | -1.31 | 0 | 4.5 | 0 | miRNAWalker2 validate; MirTarget; miRanda | -0.82 | 0 | NA | |
| 38 | hsa-miR-139-5p | BUB1 | -2.11 | 0 | 4.05 | 0 | miRanda | -0.98 | 0 | NA | |
| 39 | hsa-miR-199a-5p | BUB1 | -1.99 | 0 | 4.05 | 0 | miRanda | -0.29 | 0 | NA | |
| 40 | hsa-miR-542-3p | BUB1 | -1.31 | 0 | 4.05 | 0 | miRanda | -0.67 | 0 | NA | |
| 41 | hsa-miR-142-3p | BUB1B | -1.42 | 0 | 3.86 | 0 | miRanda | -0.2 | 0.01193 | NA | |
| 42 | hsa-miR-192-5p | BUB1B | -0.5 | 0.00345 | 3.86 | 0 | miRNAWalker2 validate | -0.22 | 0.01192 | NA | |
| 43 | hsa-miR-193b-3p | BUB1B | -0.17 | 0.27202 | 3.86 | 0 | miRNAWalker2 validate | -0.2 | 0.04744 | NA | |
| 44 | hsa-miR-215-5p | BUB1B | -0.98 | 3.0E-5 | 3.86 | 0 | miRNAWalker2 validate | -0.16 | 0.00993 | NA | |
| 45 | hsa-miR-22-3p | BUB1B | -0.63 | 0 | 3.86 | 0 | miRNAWalker2 validate | -1.6 | 0 | NA | |
| 46 | hsa-miR-486-5p | BUB1B | -1.78 | 0 | 3.86 | 0 | miRanda | -0.42 | 0 | NA | |
| 47 | hsa-let-7a-3p | CCNA2 | -0.57 | 0 | 3.37 | 0 | MirTarget | -0.51 | 4.0E-5 | NA | |
| 48 | hsa-let-7b-3p | CCNA2 | -1.22 | 0 | 3.37 | 0 | MirTarget | -0.73 | 0 | NA | |
| 49 | hsa-let-7b-5p | CCNA2 | -0.96 | 0 | 3.37 | 0 | miRNAWalker2 validate; miRTarBase | -0.52 | 0 | NA | |
| 50 | hsa-let-7f-1-3p | CCNA2 | -0.7 | 0 | 3.37 | 0 | MirTarget | -0.41 | 1.0E-5 | NA | |
| 51 | hsa-miR-130a-3p | CCNA2 | -1.53 | 0 | 3.37 | 0 | miRNATAP | -0.39 | 0 | NA | |
| 52 | hsa-miR-199a-5p | CCNA2 | -1.99 | 0 | 3.37 | 0 | miRanda | -0.27 | 0 | NA | |
| 53 | hsa-miR-22-3p | CCNA2 | -0.63 | 0 | 3.37 | 0 | MirTarget | -1.22 | 0 | 25596928 | The sequence of miR-22 which is conserved in mice rats humans and other mammalians aligns with the sequence of 3'-UTR of CCNA2; Chenodeoxycholic acid treatment and miR-22 mimics reduced CCNA2 protein and increased the number of G0/G1 Huh7 and HCT116 cells; In humans the expression levels of miR-22 and CCNA2 are inversely correlated in liver and colon cancers |
| 54 | hsa-miR-27b-3p | CCNA2 | -0.82 | 0 | 3.37 | 0 | miRNATAP | -0.54 | 0 | NA | |
| 55 | hsa-miR-29a-3p | CCNA2 | -0.86 | 0 | 3.37 | 0 | MirTarget | -0.88 | 0 | NA | |
| 56 | hsa-miR-29b-1-5p | CCNA2 | -0.54 | 0.00103 | 3.37 | 0 | MirTarget | -0.33 | 4.0E-5 | NA | |
| 57 | hsa-miR-29b-3p | CCNA2 | -0.35 | 0.01214 | 3.37 | 0 | MirTarget | -0.59 | 0 | NA | |
| 58 | hsa-miR-29c-3p | CCNA2 | -1.44 | 0 | 3.37 | 0 | MirTarget | -0.92 | 0 | NA | |
| 59 | hsa-miR-374b-5p | CCNA2 | -0.31 | 0.00301 | 3.37 | 0 | mirMAP | -0.33 | 0.01143 | NA | |
| 60 | hsa-miR-486-5p | CCNA2 | -1.78 | 0 | 3.37 | 0 | miRanda | -0.28 | 0 | NA | |
| 61 | hsa-let-7b-5p | CCNB1 | -0.96 | 0 | 3.16 | 0 | miRNAWalker2 validate | -0.54 | 0 | NA | |
| 62 | hsa-miR-139-5p | CCNB1 | -2.11 | 0 | 3.16 | 0 | miRanda | -0.8 | 0 | NA | |
| 63 | hsa-miR-142-5p | CCNB1 | -1.45 | 0 | 3.16 | 0 | MirTarget | -0.15 | 0.01528 | NA | |
| 64 | hsa-miR-192-5p | CDC20 | -0.5 | 0.00345 | 4.44 | 0 | miRNAWalker2 validate | -0.26 | 0.00747 | NA | |
| 65 | hsa-miR-215-5p | CDC20 | -0.98 | 3.0E-5 | 4.44 | 0 | miRNAWalker2 validate | -0.21 | 0.0025 | NA | |
| 66 | hsa-miR-23b-3p | CDC20 | -0.53 | 0 | 4.44 | 0 | miRNAWalker2 validate | -0.73 | 0 | NA | |
| 67 | hsa-miR-30a-5p | CDC20 | -0.63 | 0.00011 | 4.44 | 0 | miRNAWalker2 validate | -0.69 | 0 | NA | |
| 68 | hsa-miR-29c-3p | CDC23 | -1.44 | 0 | 0.46 | 0 | miRNAWalker2 validate | -0.14 | 0 | NA | |
| 69 | hsa-miR-146b-5p | CDH1 | 0.42 | 0.04574 | -0.93 | 4.0E-5 | miRanda | -0.21 | 6.0E-5 | NA | |
| 70 | hsa-miR-185-5p | CDH1 | 0.48 | 0 | -0.93 | 4.0E-5 | MirTarget | -0.45 | 8.0E-5 | 27212161; 24025511 | We also found that ectopic expression of miR-185 reversed EMT via the up-regulation of E-cadherin and down-regulation of vimentin in epithelial and mesenchymal HCC cells;After transfection of miR-185 inhibitor into KYSE30 the expression of E-cadherin a downstream protein of Six1 was observed under confocal microscope; After transfection of miR-185 inhibitorthe expression level of E-cadherin decreased |
| 71 | hsa-miR-186-5p | CDH1 | -0.06 | 0.53529 | -0.93 | 4.0E-5 | mirMAP | -0.27 | 0.01827 | NA | |
| 72 | hsa-miR-616-5p | CDH1 | 0.15 | 0.40284 | -0.93 | 4.0E-5 | MirTarget; mirMAP | -0.14 | 0.02086 | NA | |
| 73 | hsa-miR-139-5p | CDK1 | -2.11 | 0 | 3.6 | 0 | miRanda | -0.84 | 0 | NA | |
| 74 | hsa-miR-193b-3p | CDK1 | -0.17 | 0.27202 | 3.6 | 0 | miRNAWalker2 validate | -0.25 | 0.00582 | NA | |
| 75 | hsa-miR-195-3p | CDK1 | -1.09 | 0 | 3.6 | 0 | MirTarget | -0.37 | 0 | NA | |
| 76 | hsa-miR-378a-5p | CDK1 | -1.59 | 0 | 3.6 | 0 | MirTarget | -0.55 | 0 | NA | |
| 77 | hsa-miR-486-5p | CDK1 | -1.78 | 0 | 3.6 | 0 | miRanda | -0.36 | 0 | NA | |
| 78 | hsa-miR-139-5p | CDK7 | -2.11 | 0 | 0.49 | 0 | miRanda | -0.14 | 0 | NA | |
| 79 | hsa-miR-542-3p | CDK7 | -1.31 | 0 | 0.49 | 0 | miRanda | -0.18 | 0 | NA | |
| 80 | hsa-miR-590-3p | CDK7 | -0.47 | 2.0E-5 | 0.49 | 0 | miRanda | -0.18 | 0 | NA | |
| 81 | hsa-miR-181a-5p | CDKN1B | 0.25 | 0.05519 | -0.23 | 0.00482 | miRNAWalker2 validate; miRTarBase | -0.13 | 1.0E-5 | NA | |
| 82 | hsa-miR-221-3p | CDKN1B | 1.12 | 0 | -0.23 | 0.00482 | miRNAWalker2 validate; miRTarBase; MirTarget; miRNATAP | -0.15 | 0 | 20146005; 23637992; 19953484; 23939688; 19126397; 23967190; 17569667; 22992757; 17721077; 20461750 | Matched HCC and adjacent non-cancerous samples were assayed for the expression of miR-221 and three G1/S transition inhibitors: p27Kip1 p21WAF1/Cip1and TGF-β1 by in situ hybridization and immunohistochemistry respectively; Real time qRT-PCR was used to investigate miR-221 and p27Kip1 transcripts in different clinical stages; In result miR-221 and TGF-β1 are frequently up-regulated in HCC while p27Kip1 and p21WAF1/Cip1 proteins are frequently down-regulated; In conclusion miR-221 is important in tumorigenesis of HCC possibly by specifically down-regulating p27Kip1 a cell-cycle inhibitor;miR-221 knockdown not only blocked cell cycle progression induced cell apoptosis and inhibited cell proliferation in-vitro but it also inhibited in-vivo tumor growth by targeting p27kip1;Based on bioinformatic analysis we found that the seed sequences of miR-221 and miR-222 coincide with each other and p27kip1 is a target for miRNA-221/222;A Slug/miR-221 network has been suggested linking miR-221 activity with the downregulation of a Slug repressor leading to Slug/miR-221 upregulation and p27Kip1 downregulation; Interference with this process can be achieved using antisense miRNA antagomiR molecules targeting miR-221 inducing the downregulation of Slug and the upregulation of p27Kip1;Moreover a series of functional assays demonstrated that mir-221 could directly inhibit cKit p27Kip1 and possibly other pivotal proteins in melanoma;Additionally the PDGF-dependent increase in cell proliferation appears to be mediated by inhibition of a specific target of miR-221 and down-regulation of p27Kip1;miR 221 and miR 222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1; In all cell lines tested we show an inverse relationship between the expression of miR-221 and miR-222 and the cell cycle inhibitor p27Kip1; Consistently miR-221 and miR-222 knock-down through antisense LNA oligonucleotides increases p27Kip1 in PC3 cells and strongly reduces their clonogenicity in vitro;Peptide nucleic acids targeting miR 221 modulate p27Kip1 expression in breast cancer MDA MB 231 cells; Targeting miR-221 by PNA resulted in i lowering of the hybridization levels of miR-221 measured by RT-qPCR ii upregulation of p27Kip1 gene expression measured by RT-qPCR and western blot analysis;Antagonism of either microRNA 221 or 222 in glioblastoma cells also caused an increase in p27Kip1 levels and enhanced expression of the luciferase reporter gene fused to the p27Kip1 3'UTR;MiR 221 and MiR 222 alterations in sporadic ovarian carcinoma: Relationship to CDKN1B CDKNIC and overall survival; miR-221 and miR-222 negatively regulate expression of CDKN1B p27 and CDKN1C p57 two cell cycle regulators expressed in ovarian surface epithelium and down-regulated in ovarian carcinomas; In contrast CDKN1B expression was not associated with miR-221 or miR-222 expression |
| 83 | hsa-miR-222-3p | CDKN1B | 1.09 | 0 | -0.23 | 0.00482 | miRNAWalker2 validate; miRTarBase; MirTarget; miRNATAP | -0.14 | 0 | 19953484; 26912358; 24895988; 24137356; 17569667; 27282281; 20461750 | Based on bioinformatic analysis we found that the seed sequences of miR-221 and miR-222 coincide with each other and p27kip1 is a target for miRNA-221/222;Besides microvesicle marker characterization we evidenced that miR-222 exosomal expression mostly reflected its abundance in the cells of origin correctly paralleled by repression of its target genes such as p27Kip1 and induction of the PI3K/AKT pathway thus confirming its functional implication in cancer;MiR-222 plays an important role in the tumorigenesis of CC possibly by specifically down-regulating p27Kip1 and PTEN;miR 222 is upregulated in epithelial ovarian cancer and promotes cell proliferation by downregulating P27kip1; miR-222 upregulation induced an enhancement of ovarian cancer cell proliferation potential possibly by downregulating its target P27Kip1; A bioinformatic analysis showed that the 3'-UTR of the P27Kip1 mRNA contained a highly-conserved putative miR-222 binding site; Luciferase reporter assays demonstrated that P27Kip1 was a direct target of miR-222; Consistently there was an inverse correlation between the P27Kip1 and miR-222 expression levels in the ovarian cancer cell lines and tissues;miR 221 and miR 222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1; In all cell lines tested we show an inverse relationship between the expression of miR-221 and miR-222 and the cell cycle inhibitor p27Kip1; Consistently miR-221 and miR-222 knock-down through antisense LNA oligonucleotides increases p27Kip1 in PC3 cells and strongly reduces their clonogenicity in vitro;miR 222 confers the resistance of breast cancer cells to Adriamycin through suppression of p27kip1 expression; Immunofluorescence showed that miR-222 altered the subcellular location of p27kip1 in nucleus; The results showed that downregulation of miR-222 in MCF-7/Adr increased sensitivity to Adr and Adr-induced apoptosis and arrested the cells in G1 phase accompanied by more expressions of p27kip1 especially in nucleus; Taken together the results found that miR-222 induced Adr-resistance at least in part via suppressing p27kip1 expression and altering its subcellular localization and miR-222 inhibitors could reverse Adr-resistance of breast cancer cells;MiR 221 and MiR 222 alterations in sporadic ovarian carcinoma: Relationship to CDKN1B CDKNIC and overall survival; miR-221 and miR-222 negatively regulate expression of CDKN1B p27 and CDKN1C p57 two cell cycle regulators expressed in ovarian surface epithelium and down-regulated in ovarian carcinomas; In contrast CDKN1B expression was not associated with miR-221 or miR-222 expression |
| 84 | hsa-miR-24-3p | CDKN1B | -0.26 | 0.0069 | -0.23 | 0.00482 | miRNAWalker2 validate; miRNATAP | -0.13 | 0.00294 | 26847530; 26044523 | The biological significance of miR-24 expression in prostate cancer cells was assessed by a series of in vitro bioassays and the effect on proposed targets p27 CDKN1B and p16 CDK2NA was investigated;With the bioinformatic method we further identified that p27Kip1 is a direct target of miR-24-3p and its protein level was negatively regulated by miR-24-3p |
| 85 | hsa-miR-98-5p | CDKN1B | -0.05 | 0.71591 | -0.23 | 0.00482 | miRNAWalker2 validate | -0.15 | 0 | NA | |
| 86 | hsa-miR-107 | CDKN2B | 0.24 | 0.01708 | 1.37 | 0 | PITA | -0.22 | 0.01132 | NA | |
| 87 | hsa-miR-126-5p | CDKN2B | -0.43 | 7.0E-5 | 1.37 | 0 | mirMAP | -0.33 | 5.0E-5 | NA | |
| 88 | hsa-miR-144-3p | CDKN2B | -2.98 | 0 | 1.37 | 0 | MirTarget | -0.17 | 0 | NA | |
| 89 | hsa-miR-382-5p | CDKN2B | -0.72 | 0.00849 | 1.37 | 0 | mirMAP | -0.1 | 0.00159 | NA | |
| 90 | hsa-miR-450b-5p | CDKN2B | -1.34 | 0 | 1.37 | 0 | mirMAP | -0.18 | 0.00085 | NA | |
| 91 | hsa-miR-451a | CDKN2B | -2.1 | 0 | 1.37 | 0 | MirTarget | -0.16 | 0 | NA | |
| 92 | hsa-miR-486-5p | CDKN2B | -1.78 | 0 | 1.37 | 0 | miRanda | -0.19 | 0 | NA | |
| 93 | hsa-miR-450b-5p | CDKN2C | -1.34 | 0 | 2.09 | 0 | miRNATAP | -0.41 | 0 | NA | |
| 94 | hsa-miR-542-3p | CDKN2C | -1.31 | 0 | 2.09 | 0 | miRanda | -0.52 | 0 | NA | |
| 95 | hsa-miR-15a-5p | CHUK | 0.35 | 0.00077 | -0.2 | 0.00863 | miRNAWalker2 validate; miRTarBase; MirTarget | -0.12 | 0.00057 | NA | |
| 96 | hsa-miR-15b-5p | CHUK | 0.23 | 0.08248 | -0.2 | 0.00863 | MirTarget | -0.12 | 2.0E-5 | NA | |
| 97 | hsa-miR-16-5p | CHUK | -0.4 | 0.0001 | -0.2 | 0.00863 | miRNAWalker2 validate; miRTarBase; MirTarget | -0.15 | 3.0E-5 | NA | |
| 98 | hsa-miR-23a-3p | CHUK | -0.18 | 0.13598 | -0.2 | 0.00863 | MirTarget | -0.1 | 0.00114 | NA | |
| 99 | hsa-miR-339-5p | CHUK | 0.28 | 0.03557 | -0.2 | 0.00863 | miRanda | -0.12 | 1.0E-5 | NA | |
| 100 | hsa-miR-590-5p | CHUK | -0.1 | 0.31003 | -0.2 | 0.00863 | miRanda | -0.12 | 0.00129 | NA | |
| 101 | hsa-miR-330-3p | CTNNB1 | -0.33 | 0.03161 | 0 | 0.98356 | MirTarget; PITA; miRNATAP | -0.13 | 0 | NA | |
| 102 | hsa-miR-331-3p | CTNNB1 | -0.28 | 0.03738 | 0 | 0.98356 | miRNAWalker2 validate | -0.11 | 0.00027 | NA | |
| 103 | hsa-miR-27a-3p | CUL1 | -0.37 | 0.00876 | -0.12 | 0.10228 | miRNAWalker2 validate | -0.1 | 4.0E-5 | NA | |
| 104 | hsa-miR-30b-5p | CUL2 | -0.54 | 2.0E-5 | 0.22 | 0.00078 | MirTarget; mirMAP; miRNATAP | -0.1 | 3.0E-5 | NA | |
| 105 | hsa-miR-146a-5p | EGFR | -0.74 | 0.00077 | -1.02 | 0 | miRNAWalker2 validate | -0.22 | 0 | 24895573; 25242818; 22161865; 25596948; 25417703; 23555954; 24839931; 21632853 | Furthermore western blot showed that miR-146a mimic downregulated EGFR ERK1/2 and stat5 signalings; These effects were less potent compared to that of a siRNA targeting EGFR a known target gene of miR-146a; Moreover miR-146a mimic could enhance the cell growth inhibition and apoptosis induction impact of various EGFR targeting agents;Interestingly re-expression of miR-146a inhibited the invasive capacity of Colo357 and Panc-1 PC cells with concomitant down-regulation of EGFR and IRAK-1; Most importantly we found that the treatment of PC cells with "natural agents" 33'-diinodolylmethane DIM or isoflavone led to an increase in the expression of miR-146a and consequently down-regulated the expression of EGFR MTA-2 IRAK-1 and NF-κB resulting in the inhibition of invasion of Colo357 and Panc-1 cells;MiR 146a suppresses tumor growth and progression by targeting EGFR pathway and in a p ERK dependent manner in castration resistant prostate cancer; Mechanistic studies revealed that miR-146a repressed the expression of EGFR through binding to its 3'-untranslated region; Our findings suggest that ubiquitous loss of miR-146a is a critical mechanism for overexpression of EGFR in CRPC which is crucial to better understanding the pathogenesis of CRPC;Furthermore the expressions of bax and cleaved-caspase-3 mainly were increased in control and overexpression miR-146a groups however the expression of EGFR was inverse; All the results demonstrated that quercetin exhibited excellent effect on inhibiting cell proliferation in human breast cancer cells which was performed by up-regulating miR-146a expression then via inducing apoptosis through caspase-3 activation and mitochondrial-dependent pathways and inhibiting invasion through down-regulating the expression of EGFR;Here we report a previously unrecognized posttranscriptional mechanism by which BRCA1 regulates EGFR expression through the induction of miR-146a; We show that BRCA1 binds to MIR146A promoter and activates transcription which in turn attenuates EGFR expression;In functional experiments miR-146a suppressed cell growth induced cellular apoptosis and inhibited EGFR downstream signaling in five NSCLC cell lines H358 H1650 H1975 HCC827 and H292 miR-146a also inhibited the migratory capacity of these NSCLC cells; On the other hand miR-146a enhanced the inhibition of cell proliferation by drugs targeting EGFR including both TKIs gefitinib erlotinib and afatinib and a monoclonal antibody cetuximab; Our results suggest that these effects of miR-146a are due to its targeting of EGFR and NF-κB signaling;Deregulation of miR 146a expression in a mouse model of pancreatic cancer affecting EGFR signaling; Treatment of PC cells with CDF a novel synthetic compound led to re-expression of miR-146a resulting in the down-regulation of EGFR expression; Further knock-down of miR-146a in AsPC-1 cells led to the up-regulation of EGFR expression and showed increased clonogenic growth; In addition knock-down of EGFR by EGFR siRNA transfection of parental AsPC-1 cells and AsPC-1 cells stably transfected with pre-miR-146a resulted in decreased invasive capacity which was further confirmed by reduced luciferase activity in cells transfected with pMIR-Luc reporter vector containing miR-146a binding site; Collectively these results suggest that the loss of expression of miR-146a is a fundamental mechanism for over-expression of EGFR signaling and that re-expression of miR-146a by CDF treatment could be useful in designing personalized strategy for the treatment of human PC;The regulation of EGFR and IRAK1 by miR-146a was examined with miR-146a-transfected gastric cancer cells; Ectopic expression of miR-146a inhibited migration and invasion and downregulated EGFR and IRAK1 expression in gastric cancer cells; MiR-146a targeting of EGFR and IRAK1 is an independent prognostic factor in gastric cancer cases |
| 106 | hsa-miR-146b-5p | EGFR | 0.42 | 0.04574 | -1.02 | 0 | miRNATAP | -0.22 | 0 | NA | |
| 107 | hsa-miR-148b-5p | EGFR | 0.3 | 0.02557 | -1.02 | 0 | mirMAP | -0.23 | 0.00227 | NA | |
| 108 | hsa-miR-155-5p | EGFR | 0.01 | 0.95651 | -1.02 | 0 | miRNAWalker2 validate; MirTarget | -0.13 | 0.01158 | NA | |
| 109 | hsa-miR-17-5p | EGFR | 0.7 | 2.0E-5 | -1.02 | 0 | TargetScan | -0.16 | 0.00764 | NA | |
| 110 | hsa-miR-188-5p | EGFR | 1.12 | 0 | -1.02 | 0 | mirMAP | -0.3 | 0 | NA | |
| 111 | hsa-miR-21-5p | EGFR | 1.51 | 0 | -1.02 | 0 | miRNAWalker2 validate; miRTarBase | -0.44 | 0 | 24198203; 20113523; 24012640; 24331411; 26563758; 19597153; 26026961; 20048743 | In radically resected NSCLC patients the expression levels of miR-21 10b in patients with EGFR mutation were much higher than those without mutation;Thus the miR-21 inhibitor might interrupt the activity of EGFR pathways independently of PTEN status;Further the expression of miR-21 is regulated by EGFR via the activation of β-catenin and AP-1; These data indicate that a feedback loop exists between miR-21 and EGFR; These results clarify a novel association between miR-21 and EGFR in the regulation of cancer cell progression;MiR 21 overexpression is associated with acquired resistance of EGFR TKI in non small cell lung cancer;Higher expression levels of miR-21 AmiR-27a and miR-218 detected in this study suggest potential roles of these miRNAs in primary resistance to EGFR-TKI in advanced NSCLC patients with EGFR exon 19 deletion mutations;MiR 21 is an EGFR regulated anti apoptotic factor in lung cancer in never smokers; The changes in expression of some of these miRNAs including miR-21 were more remarkable in cases with EGFR mutations than in those without these mutations; In the never-smoker-derived lung adenocarcinoma cell line H3255 with mutant EGFR and high levels of p-EGFR and miR-21 antisense inhibition of miR-21 enhanced AG1478-induced apoptosis; In a never-smoker-derived adenocarcinoma cell line H441 with wild-type EGFR the antisense miR-21 not only showed the additive effect with AG1478 but also induced apoptosis by itself; These results suggest that aberrantly increased expression of miR-21 which is enhanced further by the activated EGFR signaling pathway plays a significant role in lung carcinogenesis in never-smokers as well as in smokers and is a potential therapeutic target in both EGFR-mutant and wild-type cases;Nickel may contribute to EGFR mutation and synergistically promotes tumor invasion in EGFR mutated lung cancer via nickel induced microRNA 21 expression;Downregulation of miR 21 inhibits EGFR pathway and suppresses the growth of human glioblastoma cells independent of PTEN status |
| 112 | hsa-miR-29a-5p | EGFR | -0.11 | 0.34962 | -1.02 | 0 | mirMAP | -0.46 | 0 | 27477273 | Feedback Loop Regulation of SCAP/SREBP 1 by miR 29 Modulates EGFR Signaling Driven Glioblastoma Growth |
| 113 | hsa-miR-32-3p | EGFR | 0.22 | 0.20722 | -1.02 | 0 | mirMAP | -0.24 | 7.0E-5 | NA | |
| 114 | hsa-miR-362-5p | EGFR | 0.72 | 2.0E-5 | -1.02 | 0 | mirMAP | -0.25 | 3.0E-5 | NA | |
| 115 | hsa-miR-3682-3p | EGFR | 0.81 | 1.0E-5 | -1.02 | 0 | mirMAP | -0.13 | 0.025 | NA | |
| 116 | hsa-miR-374b-3p | EGFR | -0.14 | 0.30532 | -1.02 | 0 | mirMAP | -0.2 | 0.00751 | NA | |
| 117 | hsa-miR-455-5p | EGFR | -0.27 | 0.05813 | -1.02 | 0 | miRanda | -0.23 | 0.00136 | NA | |
| 118 | hsa-miR-501-5p | EGFR | 1.15 | 0 | -1.02 | 0 | mirMAP | -0.23 | 2.0E-5 | NA | |
| 119 | hsa-miR-590-5p | EGFR | -0.1 | 0.31003 | -1.02 | 0 | miRanda; mirMAP | -0.28 | 0.00479 | NA | |
| 120 | hsa-miR-618 | EGFR | 0.14 | 0.51715 | -1.02 | 0 | mirMAP | -0.1 | 0.03801 | NA | |
| 121 | hsa-miR-769-5p | EGFR | 0.22 | 0.03334 | -1.02 | 0 | mirMAP | -0.5 | 0 | NA | |
| 122 | hsa-miR-877-5p | EGFR | 1.36 | 0 | -1.02 | 0 | mirMAP | -0.25 | 0 | NA | |
| 123 | hsa-miR-15a-5p | EGLN1 | 0.35 | 0.00077 | 0.08 | 0.4055 | MirTarget | -0.2 | 0 | NA | |
| 124 | hsa-miR-16-2-3p | EGLN1 | -0.03 | 0.80516 | 0.08 | 0.4055 | mirMAP | -0.15 | 0 | NA | |
| 125 | hsa-miR-16-5p | EGLN1 | -0.4 | 0.0001 | 0.08 | 0.4055 | MirTarget | -0.18 | 2.0E-5 | NA | |
| 126 | hsa-miR-17-5p | EGLN1 | 0.7 | 2.0E-5 | 0.08 | 0.4055 | TargetScan | -0.1 | 9.0E-5 | NA | |
| 127 | hsa-miR-186-5p | EGLN1 | -0.06 | 0.53529 | 0.08 | 0.4055 | mirMAP | -0.14 | 0.00251 | NA | |
| 128 | hsa-miR-1976 | EGLN1 | -0.43 | 0.00325 | 0.08 | 0.4055 | MirTarget | -0.12 | 9.0E-5 | NA | |
| 129 | hsa-miR-590-3p | EGLN1 | -0.47 | 2.0E-5 | 0.08 | 0.4055 | miRanda; mirMAP | -0.12 | 0.00351 | NA | |
| 130 | hsa-miR-590-5p | EGLN1 | -0.1 | 0.31003 | 0.08 | 0.4055 | miRanda | -0.2 | 1.0E-5 | NA | |
| 131 | hsa-miR-10b-3p | ETS1 | 2.77 | 0 | -0.89 | 0 | mirMAP | -0.11 | 2.0E-5 | NA | |
| 132 | hsa-miR-1180-3p | ETS1 | 1.14 | 0 | -0.89 | 0 | MirTarget | -0.29 | 0 | NA | |
| 133 | hsa-miR-130b-5p | ETS1 | 0.17 | 0.33761 | -0.89 | 0 | MirTarget | -0.12 | 0.00351 | NA | |
| 134 | hsa-miR-148b-5p | ETS1 | 0.3 | 0.02557 | -0.89 | 0 | MirTarget | -0.14 | 0.00795 | NA | |
| 135 | hsa-miR-16-1-3p | ETS1 | 0.39 | 0.00112 | -0.89 | 0 | MirTarget | -0.14 | 0.01763 | NA | |
| 136 | hsa-miR-186-5p | ETS1 | -0.06 | 0.53529 | -0.89 | 0 | mirMAP | -0.15 | 0.04115 | NA | |
| 137 | hsa-miR-193a-3p | ETS1 | -0.12 | 0.30939 | -0.89 | 0 | miRanda; miRNATAP | -0.21 | 0.00092 | NA | |
| 138 | hsa-miR-221-3p | ETS1 | 1.12 | 0 | -0.89 | 0 | miRTarBase; miRNATAP | -0.16 | 0.00028 | 21711453 | To close the loop we demonstrate ETS-1 as a direct target of miR-222 but not miR-221 showing the novel option of their uncoupled functions |
| 139 | hsa-miR-222-3p | ETS1 | 1.09 | 0 | -0.89 | 0 | miRNAWalker2 validate; miRTarBase; miRNATAP | -0.11 | 0.00861 | 21711453 | Constitutive activation of the ETS 1 miR 222 circuitry in metastatic melanoma; We demonstrate that the proto-oncogene ETS-1 involved in the pathogenesis of cancers of different origin is a transcriptional regulator of miR-222 by direct binding to its promoter region; Differently from 293FT cells or early stage melanomas where unphosphorylated ETS-1 represses miR-222 transcription in metastatic melanoma the constitutively Thr-38 phosphorylated fraction of ETS-1 induces miR-222; To close the loop we demonstrate ETS-1 as a direct target of miR-222 but not miR-221 showing the novel option of their uncoupled functions |
| 140 | hsa-miR-30d-3p | ETS1 | -0.12 | 0.32955 | -0.89 | 0 | mirMAP | -0.12 | 0.03442 | NA | |
| 141 | hsa-miR-362-3p | ETS1 | 0.81 | 0 | -0.89 | 0 | miRanda | -0.18 | 0.00046 | NA | |
| 142 | hsa-miR-365a-3p | ETS1 | 0.16 | 0.15325 | -0.89 | 0 | MirTarget | -0.27 | 2.0E-5 | NA | |
| 143 | hsa-miR-421 | ETS1 | 0.94 | 0 | -0.89 | 0 | miRanda; mirMAP; miRNATAP | -0.2 | 0 | NA | |
| 144 | hsa-miR-455-5p | ETS1 | -0.27 | 0.05813 | -0.89 | 0 | MirTarget; PITA; miRanda; miRNATAP | -0.23 | 0 | NA | |
| 145 | hsa-miR-501-5p | ETS1 | 1.15 | 0 | -0.89 | 0 | mirMAP | -0.1 | 0.00735 | NA | |
| 146 | hsa-miR-502-5p | ETS1 | 0.89 | 0 | -0.89 | 0 | miRNATAP | -0.11 | 0.00448 | NA | |
| 147 | hsa-miR-532-3p | ETS1 | 0.3 | 0.01463 | -0.89 | 0 | MirTarget; PITA; miRNATAP | -0.29 | 0 | NA | |
| 148 | hsa-miR-590-5p | ETS1 | -0.1 | 0.31003 | -0.89 | 0 | miRanda | -0.36 | 0 | NA | |
| 149 | hsa-miR-660-5p | ETS1 | 0.99 | 0 | -0.89 | 0 | MirTarget | -0.25 | 0 | NA | |
| 150 | hsa-miR-769-5p | ETS1 | 0.22 | 0.03334 | -0.89 | 0 | miRNATAP | -0.21 | 0.00233 | NA |
| Num | GO | Overlap | Size | P Value | Adj. P Value |
|---|---|---|---|---|---|
| 1 | REGULATION OF CELL CYCLE | 27 | 949 | 2.505e-21 | 1.166e-17 |
| 2 | PROTEIN PHOSPHORYLATION | 26 | 944 | 4.089e-20 | 9.513e-17 |
| 3 | NEGATIVE REGULATION OF CELL CYCLE | 19 | 433 | 3.251e-18 | 5.042e-15 |
| 4 | REGULATION OF CELL CYCLE PROCESS | 20 | 558 | 1.802e-17 | 1.677e-14 |
| 5 | CELL CYCLE PROCESS | 25 | 1081 | 1.775e-17 | 1.677e-14 |
| 6 | REGULATION OF CELL PROLIFERATION | 28 | 1496 | 2.27e-17 | 1.761e-14 |
| 7 | PHOSPHORYLATION | 26 | 1228 | 2.685e-17 | 1.785e-14 |
| 8 | POSITIVE REGULATION OF MOLECULAR FUNCTION | 29 | 1791 | 2.206e-16 | 1.283e-13 |
| 9 | MITOTIC CELL CYCLE | 21 | 766 | 5.132e-16 | 2.653e-13 |
| 10 | REGULATION OF PROTEIN MODIFICATION PROCESS | 28 | 1710 | 7.243e-16 | 3.37e-13 |
| 11 | INTRACELLULAR SIGNAL TRANSDUCTION | 27 | 1572 | 9.536e-16 | 4.034e-13 |
| 12 | CELL CYCLE | 25 | 1316 | 1.761e-15 | 6.827e-13 |
| 13 | REGULATION OF PHOSPHORUS METABOLIC PROCESS | 27 | 1618 | 1.951e-15 | 6.982e-13 |
| 14 | REGULATION OF TRANSFERASE ACTIVITY | 22 | 946 | 2.561e-15 | 8.511e-13 |
| 15 | REGULATION OF MITOTIC CELL CYCLE | 17 | 468 | 6.003e-15 | 1.862e-12 |
| 16 | REGULATION OF CELL CYCLE PHASE TRANSITION | 15 | 321 | 7.829e-15 | 2.277e-12 |
| 17 | NEGATIVE REGULATION OF PROTEIN METABOLIC PROCESS | 22 | 1087 | 4.42e-14 | 1.21e-11 |
| 18 | MITOTIC CELL CYCLE CHECKPOINT | 11 | 139 | 1.395e-13 | 3.606e-11 |
| 19 | CELL CYCLE CHECKPOINT | 12 | 194 | 1.895e-13 | 4.641e-11 |
| 20 | REGULATION OF SISTER CHROMATID SEGREGATION | 9 | 67 | 2.034e-13 | 4.732e-11 |
| 21 | NEGATIVE REGULATION OF MITOTIC CELL CYCLE | 12 | 199 | 2.568e-13 | 5.69e-11 |
| 22 | POSITIVE REGULATION OF CATALYTIC ACTIVITY | 24 | 1518 | 4.543e-13 | 9.609e-11 |
| 23 | PEPTIDYL AMINO ACID MODIFICATION | 19 | 841 | 5.681e-13 | 1.149e-10 |
| 24 | NEGATIVE REGULATION OF CELL CYCLE PROCESS | 12 | 214 | 6.102e-13 | 1.183e-10 |
| 25 | POSITIVE REGULATION OF GENE EXPRESSION | 25 | 1733 | 9.29e-13 | 1.729e-10 |
| 26 | POSITIVE REGULATION OF PROTEIN MODIFICATION PROCESS | 21 | 1135 | 1.138e-12 | 2.036e-10 |
| 27 | CELL DIVISION | 15 | 460 | 1.458e-12 | 2.512e-10 |
| 28 | REGULATION OF CHROMOSOME SEGREGATION | 9 | 85 | 1.885e-12 | 3.133e-10 |
| 29 | PHOSPHATE CONTAINING COMPOUND METABOLIC PROCESS | 26 | 1977 | 2.2e-12 | 3.53e-10 |
| 30 | REGULATION OF PROTEIN CATABOLIC PROCESS | 14 | 393 | 2.79e-12 | 4.327e-10 |
| 31 | CELL CYCLE PHASE TRANSITION | 12 | 255 | 4.84e-12 | 7.264e-10 |
| 32 | POSITIVE REGULATION OF TRANSFERASE ACTIVITY | 16 | 616 | 7.183e-12 | 1.044e-09 |
| 33 | NEGATIVE REGULATION OF CELL CYCLE PHASE TRANSITION | 10 | 146 | 8.413e-12 | 1.186e-09 |
| 34 | CELL DEATH | 19 | 1001 | 1.198e-11 | 1.64e-09 |
| 35 | POSITIVE REGULATION OF PROTEIN METABOLIC PROCESS | 22 | 1492 | 2.471e-11 | 3.286e-09 |
| 36 | CELLULAR RESPONSE TO ORGANIC SUBSTANCE | 24 | 1848 | 3.044e-11 | 3.935e-09 |
| 37 | POSITIVE REGULATION OF CELL PROLIFERATION | 17 | 814 | 4.314e-11 | 5.425e-09 |
| 38 | SISTER CHROMATID SEGREGATION | 10 | 176 | 5.407e-11 | 6.62e-09 |
| 39 | SPINDLE CHECKPOINT | 6 | 25 | 6.215e-11 | 7.415e-09 |
| 40 | SIGNAL TRANSDUCTION BY PROTEIN PHOSPHORYLATION | 13 | 404 | 6.622e-11 | 7.703e-09 |
| 41 | REGULATION OF CATABOLIC PROCESS | 16 | 731 | 9.173e-11 | 1.041e-08 |
| 42 | NEGATIVE REGULATION OF CELL DEATH | 17 | 872 | 1.258e-10 | 1.394e-08 |
| 43 | POSITIVE REGULATION OF BIOSYNTHETIC PROCESS | 23 | 1805 | 1.388e-10 | 1.502e-08 |
| 44 | REGULATION OF CELL DEATH | 21 | 1472 | 1.535e-10 | 1.624e-08 |
| 45 | RESPONSE TO LIPID | 17 | 888 | 1.667e-10 | 1.724e-08 |
| 46 | POSITIVE REGULATION OF PHOSPHATE METABOLIC PROCESS | 18 | 1036 | 2.037e-10 | 1.974e-08 |
| 47 | POSITIVE REGULATION OF PHOSPHORUS METABOLIC PROCESS | 18 | 1036 | 2.037e-10 | 1.974e-08 |
| 48 | REGULATION OF ORGANELLE ORGANIZATION | 19 | 1178 | 1.957e-10 | 1.974e-08 |
| 49 | CHROMOSOME SEGREGATION | 11 | 272 | 2.084e-10 | 1.979e-08 |
| 50 | REGULATION OF KINASE ACTIVITY | 16 | 776 | 2.207e-10 | 2.054e-08 |
| 51 | REGULATION OF CELLULAR PROTEIN CATABOLIC PROCESS | 11 | 274 | 2.253e-10 | 2.056e-08 |
| 52 | RESPONSE TO ORGANIC CYCLIC COMPOUND | 17 | 917 | 2.737e-10 | 2.359e-08 |
| 53 | MITOTIC NUCLEAR DIVISION | 12 | 361 | 2.727e-10 | 2.359e-08 |
| 54 | REGULATION OF CYCLIN DEPENDENT PROTEIN KINASE ACTIVITY | 8 | 97 | 2.677e-10 | 2.359e-08 |
| 55 | RESPONSE TO ALCOHOL | 12 | 362 | 2.815e-10 | 2.381e-08 |
| 56 | CELLULAR RESPONSE TO ORGANIC CYCLIC COMPOUND | 13 | 465 | 3.736e-10 | 3.077e-08 |
| 57 | RESPONSE TO OXYGEN CONTAINING COMPOUND | 20 | 1381 | 3.769e-10 | 3.077e-08 |
| 58 | REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY | 13 | 470 | 4.257e-10 | 3.415e-08 |
| 59 | REGULATION OF NUCLEAR DIVISION | 9 | 163 | 6.936e-10 | 5.379e-08 |
| 60 | NUCLEAR CHROMOSOME SEGREGATION | 10 | 228 | 6.851e-10 | 5.379e-08 |
| 61 | SISTER CHROMATID COHESION | 8 | 111 | 7.937e-10 | 6.054e-08 |
| 62 | ORGANELLE FISSION | 13 | 496 | 8.203e-10 | 6.156e-08 |
| 63 | REGULATION OF VASCULATURE DEVELOPMENT | 10 | 233 | 8.458e-10 | 6.247e-08 |
| 64 | RESPONSE TO ENDOGENOUS STIMULUS | 20 | 1450 | 8.867e-10 | 6.447e-08 |
| 65 | NEGATIVE REGULATION OF PROTEIN MODIFICATION PROCESS | 14 | 616 | 1.051e-09 | 7.524e-08 |
| 66 | REGULATION OF MICROTUBULE BASED PROCESS | 10 | 243 | 1.271e-09 | 8.961e-08 |
| 67 | TRACHEA DEVELOPMENT | 5 | 20 | 2.152e-09 | 1.495e-07 |
| 68 | POSITIVE REGULATION OF PROTEIN CATABOLIC PROCESS | 10 | 263 | 2.727e-09 | 1.866e-07 |
| 69 | CELLULAR RESPONSE TO OXYGEN CONTAINING COMPOUND | 15 | 799 | 3.257e-09 | 2.197e-07 |
| 70 | CELLULAR RESPONSE TO STRESS | 20 | 1565 | 3.336e-09 | 2.218e-07 |
| 71 | PROTEIN UBIQUITINATION INVOLVED IN UBIQUITIN DEPENDENT PROTEIN CATABOLIC PROCESS | 8 | 134 | 3.565e-09 | 2.304e-07 |
| 72 | POSITIVE REGULATION OF PROTEIN MODIFICATION BY SMALL PROTEIN CONJUGATION OR REMOVAL | 9 | 196 | 3.531e-09 | 2.304e-07 |
| 73 | REGULATION OF CELL DIVISION | 10 | 272 | 3.767e-09 | 2.401e-07 |
| 74 | CELLULAR RESPONSE TO LIPID | 12 | 457 | 3.942e-09 | 2.478e-07 |
| 75 | REGULATION OF PROTEIN MODIFICATION BY SMALL PROTEIN CONJUGATION OR REMOVAL | 10 | 280 | 4.974e-09 | 3.086e-07 |
| 76 | LOCOMOTION | 17 | 1114 | 5.261e-09 | 3.221e-07 |
| 77 | NEGATIVE REGULATION OF CATALYTIC ACTIVITY | 15 | 829 | 5.36e-09 | 3.239e-07 |
| 78 | CELL MOTILITY | 15 | 835 | 5.907e-09 | 3.469e-07 |
| 79 | RAS PROTEIN SIGNAL TRANSDUCTION | 8 | 143 | 5.964e-09 | 3.469e-07 |
| 80 | LOCALIZATION OF CELL | 15 | 835 | 5.907e-09 | 3.469e-07 |
| 81 | ORGAN MORPHOGENESIS | 15 | 841 | 6.505e-09 | 3.737e-07 |
| 82 | CHROMOSOME ORGANIZATION | 16 | 1009 | 9.689e-09 | 5.498e-07 |
| 83 | RESPONSE TO STEROID HORMONE | 12 | 497 | 1.005e-08 | 5.634e-07 |
| 84 | POSITIVE REGULATION OF CATABOLIC PROCESS | 11 | 395 | 1.042e-08 | 5.702e-07 |
| 85 | REGULATION OF MULTICELLULAR ORGANISMAL DEVELOPMENT | 20 | 1672 | 1.036e-08 | 5.702e-07 |
| 86 | CELL CYCLE ARREST | 8 | 154 | 1.069e-08 | 5.785e-07 |
| 87 | REGULATION OF CYTOSKELETON ORGANIZATION | 12 | 502 | 1.123e-08 | 6.007e-07 |
| 88 | RESPONSE TO ABIOTIC STIMULUS | 16 | 1024 | 1.193e-08 | 6.31e-07 |
| 89 | NEGATIVE REGULATION OF CHROMOSOME SEGREGATION | 5 | 28 | 1.341e-08 | 6.934e-07 |
| 90 | TISSUE DEVELOPMENT | 19 | 1518 | 1.327e-08 | 6.934e-07 |
| 91 | REGULATION OF PROTEIN UBIQUITINATION INVOLVED IN UBIQUITIN DEPENDENT PROTEIN CATABOLIC PROCESS | 7 | 103 | 1.474e-08 | 7.536e-07 |
| 92 | NEGATIVE REGULATION OF CELL PROLIFERATION | 13 | 643 | 1.841e-08 | 9.312e-07 |
| 93 | POSITIVE REGULATION OF RESPONSE TO STIMULUS | 21 | 1929 | 2.035e-08 | 1.018e-06 |
| 94 | NEGATIVE REGULATION OF PROTEIN CATABOLIC PROCESS | 7 | 109 | 2.188e-08 | 1.083e-06 |
| 95 | POSITIVE REGULATION OF MULTICELLULAR ORGANISMAL PROCESS | 18 | 1395 | 2.268e-08 | 1.111e-06 |
| 96 | POSITIVE REGULATION OF LIGASE ACTIVITY | 7 | 110 | 2.332e-08 | 1.13e-06 |
| 97 | NEGATIVE REGULATION OF MOLECULAR FUNCTION | 16 | 1079 | 2.489e-08 | 1.194e-06 |
| 98 | TRACHEA MORPHOGENESIS | 4 | 12 | 2.683e-08 | 1.274e-06 |
| 99 | CELL PROLIFERATION | 13 | 672 | 3.095e-08 | 1.455e-06 |
| 100 | TUBE DEVELOPMENT | 12 | 552 | 3.203e-08 | 1.49e-06 |
| 101 | IMMUNE SYSTEM PROCESS | 21 | 1984 | 3.331e-08 | 1.52e-06 |
| 102 | REGULATION OF MICROTUBULE POLYMERIZATION OR DEPOLYMERIZATION | 8 | 178 | 3.318e-08 | 1.52e-06 |
| 103 | NEGATIVE REGULATION OF MITOTIC NUCLEAR DIVISION | 5 | 34 | 3.749e-08 | 1.694e-06 |
| 104 | NEGATIVE REGULATION OF TRANSFERASE ACTIVITY | 10 | 351 | 4.241e-08 | 1.898e-06 |
| 105 | REGULATION OF RESPONSE TO STRESS | 18 | 1468 | 4.966e-08 | 2.2e-06 |
| 106 | PROTEASOMAL PROTEIN CATABOLIC PROCESS | 9 | 271 | 5.856e-08 | 2.571e-06 |
| 107 | POSITIVE REGULATION OF CELLULAR PROTEIN CATABOLIC PROCESS | 8 | 192 | 5.971e-08 | 2.58e-06 |
| 108 | REGULATION OF PROTEOLYSIS | 13 | 711 | 5.988e-08 | 2.58e-06 |
| 109 | REGULATION OF CELL DIFFERENTIATION | 18 | 1492 | 6.36e-08 | 2.715e-06 |
| 110 | CELLULAR RESPONSE TO ENDOGENOUS STIMULUS | 15 | 1008 | 7.205e-08 | 3.048e-06 |
| 111 | REGULATION OF CHROMOSOME ORGANIZATION | 9 | 278 | 7.283e-08 | 3.053e-06 |
| 112 | ANAPHASE PROMOTING COMPLEX DEPENDENT CATABOLIC PROCESS | 6 | 77 | 7.442e-08 | 3.064e-06 |
| 113 | REGULATION OF LIGASE ACTIVITY | 7 | 130 | 7.415e-08 | 3.064e-06 |
| 114 | NEGATIVE REGULATION OF CATABOLIC PROCESS | 8 | 203 | 9.181e-08 | 3.747e-06 |
| 115 | CELL CYCLE G2 M PHASE TRANSITION | 7 | 138 | 1.118e-07 | 4.523e-06 |
| 116 | RESPONSE TO HORMONE | 14 | 893 | 1.14e-07 | 4.571e-06 |
| 117 | EMBRYO DEVELOPMENT | 14 | 894 | 1.155e-07 | 4.595e-06 |
| 118 | GLAND DEVELOPMENT | 10 | 395 | 1.277e-07 | 5.037e-06 |
| 119 | FC EPSILON RECEPTOR SIGNALING PATHWAY | 7 | 142 | 1.36e-07 | 5.316e-06 |
| 120 | RESPONSE TO ESTROGEN | 8 | 218 | 1.588e-07 | 6.157e-06 |
| 121 | LUNG MORPHOGENESIS | 5 | 45 | 1.608e-07 | 6.184e-06 |
| 122 | RESPONSE TO ESTRADIOL | 7 | 146 | 1.644e-07 | 6.271e-06 |
| 123 | CARTILAGE DEVELOPMENT | 7 | 147 | 1.723e-07 | 6.517e-06 |
| 124 | REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER | 19 | 1784 | 1.754e-07 | 6.581e-06 |
| 125 | REGULATION OF PROTEASOMAL UBIQUITIN DEPENDENT PROTEIN CATABOLIC PROCESS | 7 | 148 | 1.804e-07 | 6.663e-06 |
| 126 | NEGATIVE REGULATION OF NUCLEAR DIVISION | 5 | 46 | 1.8e-07 | 6.663e-06 |
| 127 | RESPONSE TO OXYGEN LEVELS | 9 | 311 | 1.889e-07 | 6.921e-06 |
| 128 | CARDIOVASCULAR SYSTEM DEVELOPMENT | 13 | 788 | 1.967e-07 | 7.096e-06 |
| 129 | CIRCULATORY SYSTEM DEVELOPMENT | 13 | 788 | 1.967e-07 | 7.096e-06 |
| 130 | EPITHELIUM DEVELOPMENT | 14 | 945 | 2.278e-07 | 8.152e-06 |
| 131 | RESPONSE TO EXTERNAL STIMULUS | 19 | 1821 | 2.419e-07 | 8.591e-06 |
| 132 | MOVEMENT OF CELL OR SUBCELLULAR COMPONENT | 16 | 1275 | 2.484e-07 | 8.755e-06 |
| 133 | RESPONSE TO DRUG | 10 | 431 | 2.859e-07 | 1e-05 |
| 134 | EMBRYO DEVELOPMENT ENDING IN BIRTH OR EGG HATCHING | 11 | 554 | 3.212e-07 | 1.115e-05 |
| 135 | NEGATIVE REGULATION OF CELLULAR COMPONENT ORGANIZATION | 12 | 684 | 3.267e-07 | 1.126e-05 |
| 136 | RESPONSE TO TOXIC SUBSTANCE | 8 | 241 | 3.415e-07 | 1.168e-05 |
| 137 | POSITIVE REGULATION OF DEVELOPMENTAL PROCESS | 15 | 1142 | 3.625e-07 | 1.231e-05 |
| 138 | POSITIVE REGULATION OF CELLULAR COMPONENT ORGANIZATION | 15 | 1152 | 4.052e-07 | 1.366e-05 |
| 139 | POSITIVE REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER | 14 | 1004 | 4.743e-07 | 1.588e-05 |
| 140 | MICROTUBULE CYTOSKELETON ORGANIZATION | 9 | 348 | 4.862e-07 | 1.616e-05 |
| 141 | INNATE IMMUNE RESPONSE ACTIVATING CELL SURFACE RECEPTOR SIGNALING PATHWAY | 6 | 106 | 5.032e-07 | 1.66e-05 |
| 142 | SMALL GTPASE MEDIATED SIGNAL TRANSDUCTION | 9 | 352 | 5.349e-07 | 1.753e-05 |
| 143 | POSITIVE REGULATION OF CELL COMMUNICATION | 17 | 1532 | 5.424e-07 | 1.765e-05 |
| 144 | CELLULAR RESPONSE TO DNA DAMAGE STIMULUS | 12 | 720 | 5.637e-07 | 1.822e-05 |
| 145 | POSITIVE REGULATION OF IMMUNE SYSTEM PROCESS | 13 | 867 | 5.843e-07 | 1.875e-05 |
| 146 | PROTEIN MODIFICATION BY SMALL PROTEIN CONJUGATION OR REMOVAL | 13 | 873 | 6.316e-07 | 2.013e-05 |
| 147 | CELL CYCLE G1 S PHASE TRANSITION | 6 | 111 | 6.607e-07 | 2.077e-05 |
| 148 | G1 S TRANSITION OF MITOTIC CELL CYCLE | 6 | 111 | 6.607e-07 | 2.077e-05 |
| 149 | POSITIVE REGULATION OF PROTEOLYSIS | 9 | 363 | 6.914e-07 | 2.159e-05 |
| 150 | NEGATIVE REGULATION OF CELL DIVISION | 5 | 60 | 6.963e-07 | 2.16e-05 |
| 151 | REGULATION OF PROTEASOMAL PROTEIN CATABOLIC PROCESS | 7 | 181 | 7.063e-07 | 2.176e-05 |
| 152 | REGULATION OF SEQUENCE SPECIFIC DNA BINDING TRANSCRIPTION FACTOR ACTIVITY | 9 | 365 | 7.237e-07 | 2.216e-05 |
| 153 | RESPONSE TO INORGANIC SUBSTANCE | 10 | 479 | 7.503e-07 | 2.282e-05 |
| 154 | REGULATION OF IMMUNE SYSTEM PROCESS | 16 | 1403 | 8.975e-07 | 2.712e-05 |
| 155 | NEGATIVE REGULATION OF CELLULAR PROTEIN CATABOLIC PROCESS | 5 | 64 | 9.639e-07 | 2.893e-05 |
| 156 | TRANSMEMBRANE RECEPTOR PROTEIN TYROSINE KINASE SIGNALING PATHWAY | 10 | 498 | 1.067e-06 | 3.183e-05 |
| 157 | CONNECTIVE TISSUE DEVELOPMENT | 7 | 194 | 1.125e-06 | 3.313e-05 |
| 158 | REGULATION OF CELL ADHESION | 11 | 629 | 1.122e-06 | 3.313e-05 |
| 159 | REGULATION OF CELLULAR COMPONENT MOVEMENT | 12 | 771 | 1.159e-06 | 3.393e-05 |
| 160 | NEGATIVE REGULATION OF ORGANELLE ORGANIZATION | 9 | 387 | 1.176e-06 | 3.42e-05 |
| 161 | REGULATION OF CARDIAC MUSCLE CELL PROLIFERATION | 4 | 29 | 1.243e-06 | 3.591e-05 |
| 162 | MITOTIC SPINDLE ORGANIZATION | 5 | 69 | 1.406e-06 | 4.037e-05 |
| 163 | CELLULAR COMPONENT DISASSEMBLY | 10 | 515 | 1.444e-06 | 4.123e-05 |
| 164 | I KAPPAB KINASE NF KAPPAB SIGNALING | 5 | 70 | 1.511e-06 | 4.286e-05 |
| 165 | MORPHOGENESIS OF AN EPITHELIUM | 9 | 400 | 1.545e-06 | 4.356e-05 |
| 166 | MICROTUBULE BASED PROCESS | 10 | 522 | 1.631e-06 | 4.57e-05 |
| 167 | FC RECEPTOR SIGNALING PATHWAY | 7 | 206 | 1.68e-06 | 4.68e-05 |
| 168 | NEGATIVE REGULATION OF DEVELOPMENTAL PROCESS | 12 | 801 | 1.727e-06 | 4.784e-05 |
| 169 | EMBRYONIC ORGAN DEVELOPMENT | 9 | 406 | 1.746e-06 | 4.807e-05 |
| 170 | ANATOMICAL STRUCTURE FORMATION INVOLVED IN MORPHOGENESIS | 13 | 957 | 1.767e-06 | 4.837e-05 |
| 171 | REPRODUCTION | 15 | 1297 | 1.809e-06 | 4.922e-05 |
| 172 | POSITIVE REGULATION OF NF KAPPAB TRANSCRIPTION FACTOR ACTIVITY | 6 | 132 | 1.826e-06 | 4.941e-05 |
| 173 | POSITIVE REGULATION OF VASCULATURE DEVELOPMENT | 6 | 133 | 1.909e-06 | 5.133e-05 |
| 174 | TISSUE MORPHOGENESIS | 10 | 533 | 1.966e-06 | 5.257e-05 |
| 175 | NEGATIVE REGULATION OF PHOSPHORUS METABOLIC PROCESS | 10 | 541 | 2.246e-06 | 5.938e-05 |
| 176 | NEGATIVE REGULATION OF PHOSPHATE METABOLIC PROCESS | 10 | 541 | 2.246e-06 | 5.938e-05 |
| 177 | POSITIVE REGULATION OF LOCOMOTION | 9 | 420 | 2.306e-06 | 6.062e-05 |
| 178 | IN UTERO EMBRYONIC DEVELOPMENT | 8 | 311 | 2.321e-06 | 6.066e-05 |
| 179 | REGULATION OF PROTEIN COMPLEX DISASSEMBLY | 7 | 217 | 2.373e-06 | 6.169e-05 |
| 180 | ORGAN FORMATION | 4 | 34 | 2.401e-06 | 6.207e-05 |
| 181 | CELLULAR RESPONSE TO STEROID HORMONE STIMULUS | 7 | 218 | 2.447e-06 | 6.256e-05 |
| 182 | REGULATION OF PROTEIN LOCALIZATION TO NUCLEUS | 7 | 218 | 2.447e-06 | 6.256e-05 |
| 183 | NEGATIVE REGULATION OF PROTEIN MODIFICATION BY SMALL PROTEIN CONJUGATION OR REMOVAL | 6 | 139 | 2.468e-06 | 6.274e-05 |
| 184 | CELLULAR RESPONSE TO HORMONE STIMULUS | 10 | 552 | 2.688e-06 | 6.76e-05 |
| 185 | REGULATION OF CELLULAR PROTEIN LOCALIZATION | 10 | 552 | 2.688e-06 | 6.76e-05 |
| 186 | ENZYME LINKED RECEPTOR PROTEIN SIGNALING PATHWAY | 11 | 689 | 2.715e-06 | 6.791e-05 |
| 187 | REGULATION OF RESPONSE TO CYTOKINE STIMULUS | 6 | 144 | 3.03e-06 | 7.538e-05 |
| 188 | TUBE MORPHOGENESIS | 8 | 323 | 3.072e-06 | 7.563e-05 |
| 189 | IMMUNE RESPONSE REGULATING CELL SURFACE RECEPTOR SIGNALING PATHWAY | 8 | 323 | 3.072e-06 | 7.563e-05 |
| 190 | POSITIVE REGULATION OF SEQUENCE SPECIFIC DNA BINDING TRANSCRIPTION FACTOR ACTIVITY | 7 | 228 | 3.292e-06 | 8.062e-05 |
| 191 | REGULATION OF CELLULAR RESPONSE TO GROWTH FACTOR STIMULUS | 7 | 229 | 3.389e-06 | 8.255e-05 |
| 192 | EMBRYONIC PLACENTA DEVELOPMENT | 5 | 83 | 3.525e-06 | 8.543e-05 |
| 193 | DIGESTIVE SYSTEM DEVELOPMENT | 6 | 148 | 3.551e-06 | 8.56e-05 |
| 194 | HEAD DEVELOPMENT | 11 | 709 | 3.573e-06 | 8.571e-05 |
| 195 | REGULATION OF ANATOMICAL STRUCTURE MORPHOGENESIS | 13 | 1021 | 3.61e-06 | 8.613e-05 |
| 196 | POSITIVE REGULATION OF CELL CYCLE | 8 | 332 | 3.763e-06 | 8.934e-05 |
| 197 | PROTEIN CATABOLIC PROCESS | 10 | 579 | 4.107e-06 | 9.701e-05 |
| 198 | CENTRAL NERVOUS SYSTEM DEVELOPMENT | 12 | 872 | 4.154e-06 | 9.763e-05 |
| 199 | ERBB2 SIGNALING PATHWAY | 4 | 39 | 4.214e-06 | 9.854e-05 |
| 200 | NEGATIVE REGULATION OF CELLULAR CATABOLIC PROCESS | 6 | 156 | 4.812e-06 | 0.0001114 |
| 201 | CELLULAR RESPONSE TO INORGANIC SUBSTANCE | 6 | 156 | 4.812e-06 | 0.0001114 |
| 202 | HEART DEVELOPMENT | 9 | 466 | 5.371e-06 | 0.0001237 |
| 203 | MITOTIC SISTER CHROMATID SEGREGATION | 5 | 91 | 5.551e-06 | 0.0001272 |
| 204 | REGULATION OF HEART GROWTH | 4 | 42 | 5.7e-06 | 0.00013 |
| 205 | REGULATION OF INNATE IMMUNE RESPONSE | 8 | 357 | 6.413e-06 | 0.0001449 |
| 206 | FOREBRAIN DEVELOPMENT | 8 | 357 | 6.413e-06 | 0.0001449 |
| 207 | POSITIVE REGULATION OF KINASE ACTIVITY | 9 | 482 | 7.052e-06 | 0.0001585 |
| 208 | NEGATIVE REGULATION OF CHROMOSOME ORGANIZATION | 5 | 96 | 7.219e-06 | 0.0001615 |
| 209 | INTRACELLULAR RECEPTOR SIGNALING PATHWAY | 6 | 168 | 7.367e-06 | 0.000164 |
| 210 | ENDOCHONDRAL BONE MORPHOGENESIS | 4 | 45 | 7.54e-06 | 0.0001671 |
| 211 | NEGATIVE REGULATION OF PROTEIN COMPLEX DISASSEMBLY | 6 | 170 | 7.884e-06 | 0.0001739 |
| 212 | SENSORY ORGAN DEVELOPMENT | 9 | 493 | 8.453e-06 | 0.0001855 |
| 213 | MEMBRANE DISASSEMBLY | 4 | 47 | 8.988e-06 | 0.0001954 |
| 214 | NUCLEAR ENVELOPE DISASSEMBLY | 4 | 47 | 8.988e-06 | 0.0001954 |
| 215 | REGULATION OF CARDIAC MUSCLE TISSUE DEVELOPMENT | 4 | 48 | 9.785e-06 | 0.0002118 |
| 216 | REGULATION OF PROTEIN LOCALIZATION | 12 | 950 | 9.925e-06 | 0.0002138 |
| 217 | REGULATION OF MUSCLE TISSUE DEVELOPMENT | 5 | 103 | 1.019e-05 | 0.0002164 |
| 218 | POSITIVE REGULATION OF EPITHELIAL CELL MIGRATION | 5 | 103 | 1.019e-05 | 0.0002164 |
| 219 | REGULATION OF MUSCLE ORGAN DEVELOPMENT | 5 | 103 | 1.019e-05 | 0.0002164 |
| 220 | RHO PROTEIN SIGNAL TRANSDUCTION | 4 | 50 | 1.153e-05 | 0.0002439 |
| 221 | REGULATION OF HYDROLASE ACTIVITY | 14 | 1327 | 1.242e-05 | 0.0002615 |
| 222 | PEPTIDYL TYROSINE MODIFICATION | 6 | 186 | 1.317e-05 | 0.000276 |
| 223 | CELLULAR RESPONSE TO LITHIUM ION | 3 | 17 | 1.375e-05 | 0.0002856 |
| 224 | REGULATION OF SISTER CHROMATID COHESION | 3 | 17 | 1.375e-05 | 0.0002856 |
| 225 | POSITIVE REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY | 7 | 289 | 1.548e-05 | 0.0003202 |
| 226 | NEGATIVE REGULATION OF RESPONSE TO STIMULUS | 14 | 1360 | 1.64e-05 | 0.0003376 |
| 227 | EPIDERMAL GROWTH FACTOR RECEPTOR SIGNALING PATHWAY | 4 | 55 | 1.69e-05 | 0.0003465 |
| 228 | CYTOSKELETON ORGANIZATION | 11 | 838 | 1.732e-05 | 0.0003492 |
| 229 | ANTIGEN RECEPTOR MEDIATED SIGNALING PATHWAY | 6 | 195 | 1.722e-05 | 0.0003492 |
| 230 | PROTEIN SUMOYLATION | 5 | 115 | 1.741e-05 | 0.0003492 |
| 231 | EMBRYONIC MORPHOGENESIS | 9 | 539 | 1.72e-05 | 0.0003492 |
| 232 | CELLULAR RESPONSE TO ALCOHOL | 5 | 115 | 1.741e-05 | 0.0003492 |
| 233 | POSITIVE REGULATION OF MUSCLE TISSUE DEVELOPMENT | 4 | 56 | 1.817e-05 | 0.0003627 |
| 234 | RESPIRATORY SYSTEM DEVELOPMENT | 6 | 197 | 1.824e-05 | 0.0003627 |
| 235 | VENTRICULAR CARDIAC MUSCLE CELL DIFFERENTIATION | 3 | 19 | 1.952e-05 | 0.0003832 |
| 236 | POSITIVE REGULATION OF CARDIAC MUSCLE CELL PROLIFERATION | 3 | 19 | 1.952e-05 | 0.0003832 |
| 237 | CARTILAGE DEVELOPMENT INVOLVED IN ENDOCHONDRAL BONE MORPHOGENESIS | 3 | 19 | 1.952e-05 | 0.0003832 |
| 238 | REGULATION OF IMMUNE RESPONSE | 11 | 858 | 2.155e-05 | 0.0004213 |
| 239 | RESPONSE TO NITROGEN COMPOUND | 11 | 859 | 2.178e-05 | 0.0004241 |
| 240 | PROTEOLYSIS | 13 | 1208 | 2.205e-05 | 0.0004275 |
| 241 | ACTIVATION OF INNATE IMMUNE RESPONSE | 6 | 204 | 2.222e-05 | 0.000429 |
| 242 | BONE GROWTH | 3 | 20 | 2.292e-05 | 0.0004406 |
| 243 | ACTIVATION OF IMMUNE RESPONSE | 8 | 427 | 2.341e-05 | 0.0004483 |
| 244 | REGULATION OF MONOOXYGENASE ACTIVITY | 4 | 60 | 2.392e-05 | 0.0004561 |
| 245 | RESPONSE TO WOUNDING | 9 | 563 | 2.426e-05 | 0.0004569 |
| 246 | POSITIVE REGULATION OF MAP KINASE ACTIVITY | 6 | 207 | 2.412e-05 | 0.0004569 |
| 247 | POSITIVE REGULATION OF IMMUNE RESPONSE | 9 | 563 | 2.426e-05 | 0.0004569 |
| 248 | MUSCLE STRUCTURE DEVELOPMENT | 8 | 432 | 2.544e-05 | 0.0004774 |
| 249 | RESPONSE TO MECHANICAL STIMULUS | 6 | 210 | 2.616e-05 | 0.0004888 |
| 250 | NEGATIVE REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY | 5 | 126 | 2.706e-05 | 0.0005037 |
| 251 | CELL DEVELOPMENT | 14 | 1426 | 2.786e-05 | 0.0005165 |
| 252 | RESPONSE TO ACID CHEMICAL | 7 | 319 | 2.918e-05 | 0.0005387 |
| 253 | POSITIVE REGULATION OF PROTEIN LOCALIZATION TO NUCLEUS | 5 | 129 | 3.031e-05 | 0.0005574 |
| 254 | REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION | 15 | 1656 | 3.462e-05 | 0.0006341 |
| 255 | NEGATIVE REGULATION OF CYTOSKELETON ORGANIZATION | 6 | 221 | 3.483e-05 | 0.0006355 |
| 256 | MORPHOGENESIS OF EMBRYONIC EPITHELIUM | 5 | 134 | 3.637e-05 | 0.0006611 |
| 257 | SKELETAL SYSTEM DEVELOPMENT | 8 | 455 | 3.679e-05 | 0.0006661 |
| 258 | RESPONSE TO METAL ION | 7 | 333 | 3.835e-05 | 0.0006916 |
| 259 | NUCLEUS ORGANIZATION | 5 | 136 | 3.905e-05 | 0.0006988 |
| 260 | GLIAL CELL DIFFERENTIATION | 5 | 136 | 3.905e-05 | 0.0006988 |
| 261 | REGULATION OF CELLULAR LOCALIZATION | 13 | 1277 | 3.945e-05 | 0.0007032 |
| 262 | PLACENTA DEVELOPMENT | 5 | 138 | 4.187e-05 | 0.0007437 |
| 263 | REGULATION OF DEFENSE RESPONSE | 10 | 759 | 4.273e-05 | 0.000756 |
| 264 | MACROMOLECULE CATABOLIC PROCESS | 11 | 926 | 4.338e-05 | 0.0007645 |
| 265 | REGULATION OF DNA METABOLIC PROCESS | 7 | 340 | 4.376e-05 | 0.0007683 |
| 266 | VASCULATURE DEVELOPMENT | 8 | 469 | 4.558e-05 | 0.0007973 |
| 267 | NEGATIVE REGULATION OF GENE EXPRESSION | 14 | 1493 | 4.626e-05 | 0.0007974 |
| 268 | POSITIVE REGULATION OF MAPK CASCADE | 8 | 470 | 4.627e-05 | 0.0007974 |
| 269 | WOUND HEALING | 8 | 470 | 4.627e-05 | 0.0007974 |
| 270 | HISTONE PHOSPHORYLATION | 3 | 25 | 4.578e-05 | 0.0007974 |
| 271 | CELLULAR RESPONSE TO OXYGEN LEVELS | 5 | 143 | 4.963e-05 | 0.0008521 |
| 272 | RESPONSE TO GROWTH FACTOR | 8 | 475 | 4.985e-05 | 0.0008528 |
| 273 | MUSCLE CELL DIFFERENTIATION | 6 | 237 | 5.143e-05 | 0.0008765 |
| 274 | REGULATION OF ORGAN GROWTH | 4 | 73 | 5.197e-05 | 0.0008825 |
| 275 | VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR SIGNALING PATHWAY | 4 | 74 | 5.482e-05 | 0.0009176 |
| 276 | T CELL RECEPTOR SIGNALING PATHWAY | 5 | 146 | 5.479e-05 | 0.0009176 |
| 277 | DNA INTEGRITY CHECKPOINT | 5 | 146 | 5.479e-05 | 0.0009176 |
| 278 | RESPONSE TO OXIDATIVE STRESS | 7 | 352 | 5.447e-05 | 0.0009176 |
| 279 | NEGATIVE REGULATION OF NITROGEN COMPOUND METABOLIC PROCESS | 14 | 1517 | 5.508e-05 | 0.0009185 |
| 280 | REGULATION OF CELL CYCLE G1 S PHASE TRANSITION | 5 | 147 | 5.66e-05 | 0.0009406 |
| 281 | REGULATION OF ENDOTHELIAL CELL DIFFERENTIATION | 3 | 27 | 5.799e-05 | 0.00095 |
| 282 | POSITIVE REGULATION OF HEART GROWTH | 3 | 27 | 5.799e-05 | 0.00095 |
| 283 | PROTEIN UBIQUITINATION | 9 | 629 | 5.749e-05 | 0.00095 |
| 284 | RESPONSE TO LITHIUM ION | 3 | 27 | 5.799e-05 | 0.00095 |
| 285 | PEPTIDYL SERINE MODIFICATION | 5 | 148 | 5.845e-05 | 0.0009543 |
| 286 | REGULATION OF GROWTH | 9 | 633 | 6.036e-05 | 0.0009821 |
| 287 | POSITIVE REGULATION OF INNATE IMMUNE RESPONSE | 6 | 246 | 6.324e-05 | 0.001025 |
| 288 | POSITIVE REGULATION OF CELL CYCLE PROCESS | 6 | 247 | 6.467e-05 | 0.001045 |
| 289 | BLOOD VESSEL MORPHOGENESIS | 7 | 364 | 6.726e-05 | 0.001079 |
| 290 | POSITIVE REGULATION OF DEFENSE RESPONSE | 7 | 364 | 6.726e-05 | 0.001079 |
| 291 | ERBB SIGNALING PATHWAY | 4 | 79 | 7.085e-05 | 0.001129 |
| 292 | BONE MORPHOGENESIS | 4 | 79 | 7.085e-05 | 0.001129 |
| 293 | POSITIVE REGULATION OF CARDIAC MUSCLE TISSUE DEVELOPMENT | 3 | 29 | 7.215e-05 | 0.001146 |
| 294 | NEGATIVE REGULATION OF MULTICELLULAR ORGANISMAL PROCESS | 11 | 983 | 7.44e-05 | 0.001178 |
| 295 | REGULATION OF FIBROBLAST PROLIFERATION | 4 | 81 | 7.813e-05 | 0.001228 |
| 296 | NUCLEAR ENVELOPE ORGANIZATION | 4 | 81 | 7.813e-05 | 0.001228 |
| 297 | POSITIVE REGULATION OF CELL ADHESION | 7 | 376 | 8.24e-05 | 0.001291 |
| 298 | REGULATION OF MAPK CASCADE | 9 | 660 | 8.315e-05 | 0.001298 |
| 299 | LEUKOCYTE MIGRATION | 6 | 259 | 8.402e-05 | 0.001305 |
| 300 | POSITIVE REGULATION OF CELL DIFFERENTIATION | 10 | 823 | 8.413e-05 | 0.001305 |
| 301 | REGULATION OF DNA REPLICATION | 5 | 161 | 8.711e-05 | 0.001347 |
| 302 | REGULATION OF CELL CELL ADHESION | 7 | 380 | 8.803e-05 | 0.001356 |
| 303 | MICROTUBULE ORGANIZING CENTER ORGANIZATION | 4 | 84 | 9.004e-05 | 0.001378 |
| 304 | CYTOKINESIS | 4 | 84 | 9.004e-05 | 0.001378 |
| 305 | PROTEIN LOCALIZATION | 15 | 1805 | 9.328e-05 | 0.001423 |
| 306 | REGULATION OF CELL DEVELOPMENT | 10 | 836 | 9.579e-05 | 0.001457 |
| 307 | NEGATIVE REGULATION OF CYCLIN DEPENDENT PROTEIN KINASE ACTIVITY | 3 | 32 | 9.736e-05 | 0.001471 |
| 308 | REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER IN RESPONSE TO HYPOXIA | 3 | 32 | 9.736e-05 | 0.001471 |
| 309 | REGULATION OF EPITHELIAL CELL MIGRATION | 5 | 166 | 0.0001006 | 0.001515 |
| 310 | NEUROGENESIS | 13 | 1402 | 0.0001028 | 0.001543 |
| 311 | RESPONSE TO CARBOHYDRATE | 5 | 168 | 0.0001065 | 0.001593 |
| 312 | G2 DNA DAMAGE CHECKPOINT | 3 | 33 | 0.0001069 | 0.001594 |
| 313 | BIOLOGICAL ADHESION | 11 | 1032 | 0.0001148 | 0.001706 |
| 314 | NEGATIVE REGULATION OF NEURON DEATH | 5 | 171 | 0.0001157 | 0.001714 |
| 315 | POSITIVE REGULATION OF EPITHELIAL TO MESENCHYMAL TRANSITION | 3 | 34 | 0.000117 | 0.001728 |
| 316 | REGULATION OF OXIDOREDUCTASE ACTIVITY | 4 | 90 | 0.0001178 | 0.001734 |
| 317 | STRIATED MUSCLE CELL DIFFERENTIATION | 5 | 173 | 0.0001222 | 0.001794 |
| 318 | ACTIVATION OF PROTEIN KINASE ACTIVITY | 6 | 279 | 0.0001263 | 0.001848 |
| 319 | CELLULAR MACROMOLECULE LOCALIZATION | 12 | 1234 | 0.000128 | 0.001867 |
| 320 | CELLULAR RESPONSE TO ACID CHEMICAL | 5 | 175 | 0.000129 | 0.001869 |
| 321 | GLIOGENESIS | 5 | 175 | 0.000129 | 0.001869 |
| 322 | REPRODUCTIVE SYSTEM DEVELOPMENT | 7 | 408 | 0.0001369 | 0.001978 |
| 323 | POSITIVE REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION | 10 | 876 | 0.0001407 | 0.002026 |
| 324 | REGULATION OF EPITHELIAL CELL PROLIFERATION | 6 | 285 | 0.0001418 | 0.002037 |
| 325 | SIGNAL TRANSDUCTION IN RESPONSE TO DNA DAMAGE | 4 | 96 | 0.0001512 | 0.002158 |
| 326 | RESPONSE TO CYTOKINE | 9 | 714 | 0.0001509 | 0.002158 |
| 327 | REGULATION OF MYELOID CELL DIFFERENTIATION | 5 | 183 | 0.0001589 | 0.002255 |
| 328 | REGULATION OF PROTEIN IMPORT | 5 | 183 | 0.0001589 | 0.002255 |
| 329 | NEGATIVE REGULATION OF CELL CYCLE G1 S PHASE TRANSITION | 4 | 98 | 0.0001637 | 0.002309 |
| 330 | POSITIVE REGULATION OF ORGAN GROWTH | 3 | 38 | 0.0001636 | 0.002309 |
| 331 | ANGIOGENESIS | 6 | 293 | 0.0001649 | 0.002317 |
| 332 | CELL JUNCTION ORGANIZATION | 5 | 185 | 0.0001672 | 0.002343 |
| 333 | NEGATIVE REGULATION OF PHOSPHORYLATION | 7 | 422 | 0.0001685 | 0.002354 |
| 334 | LIPID PHOSPHORYLATION | 4 | 99 | 0.0001703 | 0.002372 |
| 335 | EPITHELIAL CELL DEVELOPMENT | 5 | 186 | 0.0001715 | 0.002382 |
| 336 | MITOTIC DNA INTEGRITY CHECKPOINT | 4 | 100 | 0.000177 | 0.002444 |
| 337 | REGULATION OF SMOOTH MUSCLE CELL PROLIFERATION | 4 | 100 | 0.000177 | 0.002444 |
| 338 | POSITIVE REGULATION OF HYDROLASE ACTIVITY | 10 | 905 | 0.0001834 | 0.002525 |
| 339 | REGULATION OF PHOSPHATIDYLINOSITOL 3 KINASE ACTIVITY | 3 | 40 | 0.0001909 | 0.002605 |
| 340 | ENDODERMAL CELL DIFFERENTIATION | 3 | 40 | 0.0001909 | 0.002605 |
| 341 | RESPONSE TO CADMIUM ION | 3 | 40 | 0.0001909 | 0.002605 |
| 342 | RESPONSE TO REACTIVE OXYGEN SPECIES | 5 | 191 | 0.000194 | 0.002639 |
| 343 | STRESS ACTIVATED PROTEIN KINASE SIGNALING CASCADE | 4 | 103 | 0.0001984 | 0.002691 |
| 344 | EXTRACELLULAR STRUCTURE ORGANIZATION | 6 | 304 | 0.0002012 | 0.002722 |
| 345 | IMMUNE SYSTEM DEVELOPMENT | 8 | 582 | 0.0002033 | 0.002742 |
| 346 | POSITIVE REGULATION OF PROTEIN IMPORT | 4 | 104 | 0.0002059 | 0.002745 |
| 347 | CELLULAR RESPONSE TO ESTROGEN STIMULUS | 3 | 41 | 0.0002055 | 0.002745 |
| 348 | ANDROGEN RECEPTOR SIGNALING PATHWAY | 3 | 41 | 0.0002055 | 0.002745 |
| 349 | CELLULAR RESPONSE TO REACTIVE OXYGEN SPECIES | 4 | 104 | 0.0002059 | 0.002745 |
| 350 | PEPTIDYL LYSINE MODIFICATION | 6 | 312 | 0.0002315 | 0.003077 |
| 351 | REGULATION OF HEMOPOIESIS | 6 | 314 | 0.0002396 | 0.003176 |
| 352 | SKELETAL SYSTEM MORPHOGENESIS | 5 | 201 | 0.0002458 | 0.003249 |
| 353 | LABYRINTHINE LAYER DEVELOPMENT | 3 | 44 | 0.0002538 | 0.003337 |
| 354 | NEGATIVE REGULATION OF MYELOID LEUKOCYTE DIFFERENTIATION | 3 | 44 | 0.0002538 | 0.003337 |
| 355 | DEVELOPMENTAL PROCESS INVOLVED IN REPRODUCTION | 8 | 602 | 0.0002556 | 0.00335 |
| 356 | REGULATION OF MAP KINASE ACTIVITY | 6 | 319 | 0.0002608 | 0.003409 |
| 357 | CENTROSOME CYCLE | 3 | 45 | 0.0002714 | 0.003528 |
| 358 | PROTEIN LOCALIZATION TO CHROMOSOME | 3 | 45 | 0.0002714 | 0.003528 |
| 359 | PEPTIDYL THREONINE MODIFICATION | 3 | 46 | 0.0002898 | 0.003756 |
| 360 | EYE DEVELOPMENT | 6 | 326 | 0.0002929 | 0.003786 |
| 361 | TAXIS | 7 | 464 | 0.0003004 | 0.003871 |
| 362 | ENDOMEMBRANE SYSTEM ORGANIZATION | 7 | 465 | 0.0003043 | 0.003911 |
| 363 | NEGATIVE REGULATION OF PROTEOLYSIS | 6 | 329 | 0.0003076 | 0.003933 |
| 364 | SKIN DEVELOPMENT | 5 | 211 | 0.0003075 | 0.003933 |
| 365 | RESPONSE TO ANTIBIOTIC | 3 | 47 | 0.000309 | 0.003939 |
| 366 | MAMMARY GLAND DEVELOPMENT | 4 | 117 | 0.0003231 | 0.004108 |
| 367 | REGULATION OF LIPID KINASE ACTIVITY | 3 | 48 | 0.0003289 | 0.004159 |
| 368 | DIGESTIVE TRACT MORPHOGENESIS | 3 | 48 | 0.0003289 | 0.004159 |
| 369 | PHOSPHATIDYLINOSITOL 3 PHOSPHATE BIOSYNTHETIC PROCESS | 3 | 49 | 0.0003497 | 0.004397 |
| 370 | REGULATION OF NITRIC OXIDE SYNTHASE ACTIVITY | 3 | 49 | 0.0003497 | 0.004397 |
| 371 | POSITIVE REGULATION OF NUCLEOCYTOPLASMIC TRANSPORT | 4 | 121 | 0.0003672 | 0.004605 |
| 372 | POSITIVE REGULATION OF STEM CELL DIFFERENTIATION | 3 | 50 | 0.0003712 | 0.004619 |
| 373 | REGULATION OF TUMOR NECROSIS FACTOR MEDIATED SIGNALING PATHWAY | 3 | 50 | 0.0003712 | 0.004619 |
| 374 | ENDODERM FORMATION | 3 | 50 | 0.0003712 | 0.004619 |
| 375 | REGULATION OF NUCLEOCYTOPLASMIC TRANSPORT | 5 | 220 | 0.0003725 | 0.004622 |
| 376 | POSITIVE REGULATION OF MITOTIC CELL CYCLE | 4 | 123 | 0.0003908 | 0.004836 |
| 377 | NEGATIVE REGULATION OF CELL COMMUNICATION | 11 | 1192 | 0.0004013 | 0.004953 |
| 378 | INOSITOL LIPID MEDIATED SIGNALING | 4 | 124 | 0.000403 | 0.00496 |
| 379 | PROTEIN LOCALIZATION TO KINETOCHORE | 2 | 11 | 0.0004167 | 0.005076 |
| 380 | KIDNEY EPITHELIUM DEVELOPMENT | 4 | 125 | 0.0004154 | 0.005076 |
| 381 | REGULATION OF ATTACHMENT OF SPINDLE MICROTUBULES TO KINETOCHORE | 2 | 11 | 0.0004167 | 0.005076 |
| 382 | STEROID HORMONE MEDIATED SIGNALING PATHWAY | 4 | 125 | 0.0004154 | 0.005076 |
| 383 | WNT SIGNALING PATHWAY | 6 | 351 | 0.000434 | 0.005273 |
| 384 | POSITIVE REGULATION OF PHOSPHOLIPASE ACTIVITY | 3 | 53 | 0.0004411 | 0.005331 |
| 385 | POSITIVE REGULATION OF FIBROBLAST PROLIFERATION | 3 | 53 | 0.0004411 | 0.005331 |
| 386 | EPITHELIAL CELL DIFFERENTIATION | 7 | 495 | 0.0004431 | 0.005341 |
| 387 | TUBE FORMATION | 4 | 129 | 0.000468 | 0.005613 |
| 388 | CELL JUNCTION ASSEMBLY | 4 | 129 | 0.000468 | 0.005613 |
| 389 | POSITIVE REGULATION OF CELLULAR PROTEIN LOCALIZATION | 6 | 360 | 0.0004961 | 0.005866 |
| 390 | REGULATION OF ENDOTHELIAL CELL DEVELOPMENT | 2 | 12 | 0.0004992 | 0.005866 |
| 391 | HEMIDESMOSOME ASSEMBLY | 2 | 12 | 0.0004992 | 0.005866 |
| 392 | CELLULAR RESPONSE TO NITROGEN COMPOUND | 7 | 505 | 0.0004993 | 0.005866 |
| 393 | REGULATION OF ESTABLISHMENT OF ENDOTHELIAL BARRIER | 2 | 12 | 0.0004992 | 0.005866 |
| 394 | GROWTH PLATE CARTILAGE DEVELOPMENT | 2 | 12 | 0.0004992 | 0.005866 |
| 395 | BRANCHING MORPHOGENESIS OF AN EPITHELIAL TUBE | 4 | 131 | 0.000496 | 0.005866 |
| 396 | MITOTIC SISTER CHROMATID COHESION | 2 | 12 | 0.0004992 | 0.005866 |
| 397 | MAINTENANCE OF CELL NUMBER | 4 | 132 | 0.0005105 | 0.005983 |
| 398 | NEGATIVE REGULATION OF GROWTH | 5 | 236 | 0.0005131 | 0.005999 |
| 399 | POSITIVE REGULATION OF GROWTH | 5 | 238 | 0.0005331 | 0.006217 |
| 400 | REGULATION OF GTPASE ACTIVITY | 8 | 673 | 0.0005378 | 0.006256 |
| 401 | CELL MORPHOGENESIS INVOLVED IN DIFFERENTIATION | 7 | 513 | 0.0005482 | 0.006361 |
| 402 | PROTEIN LOCALIZATION TO CHROMOSOME CENTROMERIC REGION | 2 | 13 | 0.0005889 | 0.006732 |
| 403 | MITOTIC G2 DNA DAMAGE CHECKPOINT | 2 | 13 | 0.0005889 | 0.006732 |
| 404 | POSITIVE REGULATION OF CELL CELL ADHESION | 5 | 243 | 0.0005858 | 0.006732 |
| 405 | VENTRICULAR CARDIAC MUSCLE CELL DEVELOPMENT | 2 | 13 | 0.0005889 | 0.006732 |
| 406 | ACTIVATION OF MAPK ACTIVITY | 4 | 137 | 0.0005872 | 0.006732 |
| 407 | REGULATION OF BICELLULAR TIGHT JUNCTION ASSEMBLY | 2 | 13 | 0.0005889 | 0.006732 |
| 408 | REGULATION OF PHOSPHATIDYLINOSITOL 3 KINASE SIGNALING | 4 | 138 | 0.0006035 | 0.006864 |
| 409 | REGULATION OF CELL CYCLE G2 M PHASE TRANSITION | 3 | 59 | 0.0006049 | 0.006864 |
| 410 | VASCULOGENESIS | 3 | 59 | 0.0006049 | 0.006864 |
| 411 | STEM CELL PROLIFERATION | 3 | 60 | 0.0006354 | 0.007176 |
| 412 | CHONDROCYTE DIFFERENTIATION | 3 | 60 | 0.0006354 | 0.007176 |
| 413 | CARDIAC MUSCLE TISSUE DEVELOPMENT | 4 | 140 | 0.000637 | 0.007177 |
| 414 | NEGATIVE REGULATION OF KINASE ACTIVITY | 5 | 250 | 0.0006661 | 0.007407 |
| 415 | CHROMOSOME LOCALIZATION | 3 | 61 | 0.000667 | 0.007407 |
| 416 | REGULATION OF PHOSPHOLIPID METABOLIC PROCESS | 3 | 61 | 0.000667 | 0.007407 |
| 417 | CELLULAR RESPONSE TO HYDROGEN PEROXIDE | 3 | 61 | 0.000667 | 0.007407 |
| 418 | NEURON DIFFERENTIATION | 9 | 874 | 0.0006661 | 0.007407 |
| 419 | POSITIVE REGULATION OF STEM CELL PROLIFERATION | 3 | 61 | 0.000667 | 0.007407 |
| 420 | POSITIVE REGULATION OF SPROUTING ANGIOGENESIS | 2 | 14 | 0.0006858 | 0.007597 |
| 421 | REGULATION OF NEURON DEATH | 5 | 252 | 0.0006904 | 0.007631 |
| 422 | EPIDERMIS DEVELOPMENT | 5 | 253 | 0.0007029 | 0.00775 |
| 423 | REGULATION OF CARTILAGE DEVELOPMENT | 3 | 63 | 0.000733 | 0.008063 |
| 424 | REGULATION OF PHOSPHOLIPASE ACTIVITY | 3 | 64 | 0.0007676 | 0.008423 |
| 425 | NEGATIVE REGULATION OF PHOSPHOPROTEIN PHOSPHATASE ACTIVITY | 2 | 15 | 0.0007898 | 0.008607 |
| 426 | MORPHOGENESIS OF AN EPITHELIAL FOLD | 2 | 15 | 0.0007898 | 0.008607 |
| 427 | ACTIVATION OF ANAPHASE PROMOTING COMPLEX ACTIVITY | 2 | 15 | 0.0007898 | 0.008607 |
| 428 | SINGLE ORGANISM CELLULAR LOCALIZATION | 9 | 898 | 0.0008081 | 0.008785 |
| 429 | POSITIVE REGULATION OF LIPASE ACTIVITY | 3 | 66 | 0.0008397 | 0.009086 |
| 430 | LENS DEVELOPMENT IN CAMERA TYPE EYE | 3 | 66 | 0.0008397 | 0.009086 |
| 431 | CELLULAR RESPONSE TO EXTERNAL STIMULUS | 5 | 264 | 0.0008509 | 0.009187 |
| 432 | MEIOTIC CELL CYCLE PROCESS | 4 | 152 | 0.0008664 | 0.009332 |
| 433 | POSITIVE REGULATION OF ENDOTHELIAL CELL MIGRATION | 3 | 67 | 0.0008773 | 0.009384 |
| 434 | REGULATION OF DNA TEMPLATED TRANSCRIPTION IN RESPONSE TO STRESS | 3 | 67 | 0.0008773 | 0.009384 |
| 435 | REGULATION OF EPITHELIAL TO MESENCHYMAL TRANSITION | 3 | 67 | 0.0008773 | 0.009384 |
| 436 | PALLIUM DEVELOPMENT | 4 | 153 | 0.0008878 | 0.009475 |
| 437 | REGULATION OF EXIT FROM MITOSIS | 2 | 16 | 0.0009011 | 0.00955 |
| 438 | NEGATIVE REGULATION OF DNA DEPENDENT DNA REPLICATION | 2 | 16 | 0.0009011 | 0.00955 |
| 439 | POSITIVE REGULATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR SIGNALING PATHWAY | 2 | 16 | 0.0009011 | 0.00955 |
| 440 | RESPONSE TO PEPTIDE | 6 | 404 | 0.000906 | 0.009581 |
| 441 | POSITIVE REGULATION OF EPITHELIAL CELL PROLIFERATION | 4 | 154 | 0.0009096 | 0.009598 |
| 442 | ORGAN GROWTH | 3 | 68 | 0.000916 | 0.009643 |
| 443 | GASTRULATION | 4 | 155 | 0.0009318 | 0.009787 |
| 444 | CELLULAR CATABOLIC PROCESS | 11 | 1322 | 0.0009531 | 0.009949 |
| 445 | BONE DEVELOPMENT | 4 | 156 | 0.0009544 | 0.009949 |
| 446 | POSITIVE REGULATION OF DEVELOPMENTAL GROWTH | 4 | 156 | 0.0009544 | 0.009949 |
| 447 | RESPONSE TO ACTIVITY | 3 | 69 | 0.0009557 | 0.009949 |
| Num | GO | Overlap | Size | P Value | Adj. P Value |
|---|---|---|---|---|---|
| 1 | ENZYME BINDING | 32 | 1737 | 4.626e-20 | 4.297e-17 |
| 2 | PROTEIN KINASE ACTIVITY | 17 | 640 | 9.614e-13 | 4.466e-10 |
| 3 | KINASE ACTIVITY | 18 | 842 | 6.779e-12 | 2.099e-09 |
| 4 | PROTEIN SERINE THREONINE KINASE ACTIVITY | 14 | 445 | 1.473e-11 | 3.421e-09 |
| 5 | KINASE BINDING | 15 | 606 | 7.229e-11 | 1.343e-08 |
| 6 | TRANSFERASE ACTIVITY TRANSFERRING PHOSPHORUS CONTAINING GROUPS | 18 | 992 | 1.006e-10 | 1.558e-08 |
| 7 | MACROMOLECULAR COMPLEX BINDING | 20 | 1399 | 4.734e-10 | 6.282e-08 |
| 8 | RIBONUCLEOTIDE BINDING | 22 | 1860 | 1.705e-09 | 1.98e-07 |
| 9 | UBIQUITIN LIKE PROTEIN LIGASE BINDING | 10 | 264 | 2.828e-09 | 2.919e-07 |
| 10 | PROTEIN COMPLEX BINDING | 16 | 935 | 3.28e-09 | 3.047e-07 |
| 11 | ADENYL NUCLEOTIDE BINDING | 18 | 1514 | 7.947e-08 | 6.711e-06 |
| 12 | RECEPTOR BINDING | 17 | 1476 | 3.204e-07 | 2.48e-05 |
| 13 | MOLECULAR FUNCTION REGULATOR | 16 | 1353 | 5.53e-07 | 3.952e-05 |
| 14 | PROTEIN HETERODIMERIZATION ACTIVITY | 10 | 468 | 6.074e-07 | 4.03e-05 |
| 15 | ANDROGEN RECEPTOR BINDING | 4 | 39 | 4.214e-06 | 0.0002609 |
| 16 | CYCLIN DEPENDENT PROTEIN SERINE THREONINE KINASE INHIBITOR ACTIVITY | 3 | 12 | 4.493e-06 | 0.0002609 |
| 17 | HORMONE RECEPTOR BINDING | 6 | 168 | 7.367e-06 | 0.0004026 |
| 18 | PROTEIN TYROSINE KINASE ACTIVITY | 6 | 176 | 9.614e-06 | 0.0004962 |
| 19 | ENZYME REGULATOR ACTIVITY | 12 | 959 | 1.091e-05 | 0.0005336 |
| 20 | PROTEIN DIMERIZATION ACTIVITY | 13 | 1149 | 1.296e-05 | 0.0005826 |
| 21 | KINASE REGULATOR ACTIVITY | 6 | 186 | 1.317e-05 | 0.0005826 |
| 22 | HISTONE KINASE ACTIVITY | 3 | 19 | 1.952e-05 | 0.0008242 |
| 23 | PROTEIN PHOSPHATASE BINDING | 5 | 120 | 2.139e-05 | 0.000864 |
| 24 | CHROMATIN BINDING | 8 | 435 | 2.673e-05 | 0.001035 |
| 25 | PHOSPHATIDYLINOSITOL 3 KINASE ACTIVITY | 4 | 70 | 4.405e-05 | 0.001637 |
| 26 | CYCLIN DEPENDENT PROTEIN SERINE THREONINE KINASE REGULATOR ACTIVITY | 3 | 28 | 6.482e-05 | 0.002316 |
| 27 | PROTEIN SERINE THREONINE KINASE INHIBITOR ACTIVITY | 3 | 30 | 8.001e-05 | 0.002655 |
| 28 | STEROID HORMONE RECEPTOR BINDING | 4 | 81 | 7.813e-05 | 0.002655 |
| 29 | PHOSPHATASE BINDING | 5 | 162 | 8.97e-05 | 0.002873 |
| 30 | HEAT SHOCK PROTEIN BINDING | 4 | 89 | 0.0001128 | 0.003452 |
| 31 | CYCLIN DEPENDENT PROTEIN KINASE ACTIVITY | 3 | 34 | 0.000117 | 0.003452 |
| 32 | RECEPTOR SIGNALING PROTEIN ACTIVITY | 5 | 172 | 0.0001189 | 0.003452 |
| 33 | TRANSCRIPTION COACTIVATOR ACTIVITY | 6 | 296 | 0.0001742 | 0.004905 |
| 34 | X1 PHOSPHATIDYLINOSITOL 3 KINASE ACTIVITY | 3 | 43 | 0.000237 | 0.006476 |
| Num | GO | Overlap | Size | P Value | Adj. P Value |
|---|---|---|---|---|---|
| 1 | CHROMOSOME CENTROMERIC REGION | 9 | 174 | 1.237e-09 | 7.226e-07 |
| 2 | SPINDLE | 10 | 289 | 6.731e-09 | 1.965e-06 |
| 3 | MICROTUBULE CYTOSKELETON | 16 | 1068 | 2.156e-08 | 3.134e-06 |
| 4 | CHROMOSOMAL REGION | 10 | 330 | 2.373e-08 | 3.134e-06 |
| 5 | CONDENSED CHROMOSOME OUTER KINETOCHORE | 4 | 12 | 2.683e-08 | 3.134e-06 |
| 6 | KINETOCHORE | 7 | 120 | 4.266e-08 | 4.152e-06 |
| 7 | CONDENSED NUCLEAR CHROMOSOME | 6 | 85 | 1.349e-07 | 9.565e-06 |
| 8 | CYTOSKELETON | 20 | 1967 | 1.57e-07 | 9.565e-06 |
| 9 | CONDENSED NUCLEAR CHROMOSOME CENTROMERIC REGION | 4 | 18 | 1.638e-07 | 9.565e-06 |
| 10 | MICROTUBULE ORGANIZING CENTER | 12 | 623 | 1.197e-07 | 9.565e-06 |
| 11 | NUCLEAR CHROMOSOME | 11 | 523 | 1.808e-07 | 9.601e-06 |
| 12 | CYTOSKELETAL PART | 17 | 1436 | 2.166e-07 | 1.054e-05 |
| 13 | CONDENSED CHROMOSOME CENTROMERIC REGION | 6 | 102 | 4.006e-07 | 1.8e-05 |
| 14 | CHROMOSOME | 13 | 880 | 6.912e-07 | 2.883e-05 |
| 15 | CENTROSOME | 10 | 487 | 8.719e-07 | 3.303e-05 |
| 16 | ANCHORING JUNCTION | 10 | 489 | 9.048e-07 | 3.303e-05 |
| 17 | CONDENSED CHROMOSOME | 7 | 195 | 1.164e-06 | 4e-05 |
| 18 | SPINDLE POLE | 6 | 126 | 1.392e-06 | 4.515e-05 |
| 19 | CELL SUBSTRATE JUNCTION | 9 | 398 | 1.482e-06 | 4.556e-05 |
| 20 | TRANSFERASE COMPLEX | 11 | 703 | 3.294e-06 | 9.618e-05 |
| 21 | CULLIN RING UBIQUITIN LIGASE COMPLEX | 6 | 150 | 3.837e-06 | 0.0001067 |
| 22 | BETA CATENIN DESTRUCTION COMPLEX | 3 | 14 | 7.405e-06 | 0.0001966 |
| 23 | UBIQUITIN LIGASE COMPLEX | 7 | 262 | 8.195e-06 | 0.0002081 |
| 24 | CATALYTIC COMPLEX | 12 | 1038 | 2.403e-05 | 0.0005847 |
| 25 | ANAPHASE PROMOTING COMPLEX | 3 | 22 | 3.083e-05 | 0.0007203 |
| 26 | EXTRINSIC COMPONENT OF PLASMA MEMBRANE | 5 | 136 | 3.905e-05 | 0.0008771 |
| 27 | PERINUCLEAR REGION OF CYTOPLASM | 9 | 642 | 6.728e-05 | 0.001455 |
| 28 | EXTRINSIC COMPONENT OF MEMBRANE | 6 | 252 | 7.224e-05 | 0.001507 |
| 29 | PLASMA MEMBRANE PROTEIN COMPLEX | 8 | 510 | 8.199e-05 | 0.001651 |
| 30 | PROTEIN KINASE COMPLEX | 4 | 90 | 0.0001178 | 0.00224 |
| 31 | LAMELLIPODIUM | 5 | 172 | 0.0001189 | 0.00224 |
| 32 | BASEMENT MEMBRANE | 4 | 93 | 0.0001337 | 0.002441 |
| 33 | CYTOPLASMIC REGION | 6 | 287 | 0.0001473 | 0.002607 |
| 34 | SIDE OF MEMBRANE | 7 | 428 | 0.0001837 | 0.003155 |
| 35 | NUCLEAR UBIQUITIN LIGASE COMPLEX | 3 | 42 | 0.0002209 | 0.003686 |
| 36 | CELL JUNCTION | 11 | 1151 | 0.0002975 | 0.004827 |
| 37 | LATERAL PLASMA MEMBRANE | 3 | 50 | 0.0003712 | 0.005859 |
| 38 | EXTRACELLULAR MATRIX COMPONENT | 4 | 125 | 0.0004154 | 0.005936 |
| 39 | IKAPPAB KINASE COMPLEX | 2 | 11 | 0.0004167 | 0.005936 |
| 40 | WNT SIGNALOSOME | 2 | 11 | 0.0004167 | 0.005936 |
| 41 | COHESIN COMPLEX | 2 | 11 | 0.0004167 | 0.005936 |
| 42 | CELL CELL ADHERENS JUNCTION | 3 | 54 | 0.0004661 | 0.006481 |
| 43 | TRANSFERASE COMPLEX TRANSFERRING PHOSPHORUS CONTAINING GROUPS | 5 | 237 | 0.000523 | 0.007076 |
| 44 | CELL CORTEX | 5 | 238 | 0.0005331 | 0.007076 |
| 45 | CYTOPLASMIC MICROTUBULE | 3 | 57 | 0.0005466 | 0.007093 |
| 46 | SPINDLE MICROTUBULE | 3 | 58 | 0.0005752 | 0.007303 |
Over-represented Pathway
| Num | Pathway | Pathview | Overlap | Size | P Value | Adj. P Value |
|---|---|---|---|---|---|---|
| 1 | Cell_cycle_hsa04110 | 17 | 124 | 7.585e-25 | 3.944e-23 | |
| 2 | PI3K_Akt_signaling_pathway_hsa04151 | 16 | 352 | 1.328e-15 | 3.452e-14 | |
| 3 | Ras_signaling_pathway_hsa04014 | 14 | 232 | 2.031e-15 | 3.521e-14 | |
| 4 | Signaling_pathways_regulating_pluripotency_of_stem_cells_hsa04550 | 12 | 139 | 3.37e-15 | 4.381e-14 | |
| 5 | Cellular_senescence_hsa04218 | 12 | 160 | 1.865e-14 | 1.94e-13 | |
| 6 | FoxO_signaling_pathway_hsa04068 | 11 | 132 | 7.841e-14 | 6.795e-13 | |
| 7 | HIF_1_signaling_pathway_hsa04066 | 10 | 100 | 1.813e-13 | 1.347e-12 | |
| 8 | Focal_adhesion_hsa04510 | 12 | 199 | 2.568e-13 | 1.669e-12 | |
| 9 | Regulation_of_actin_cytoskeleton_hsa04810 | 12 | 208 | 4.351e-13 | 2.514e-12 | |
| 10 | Oocyte_meiosis_hsa04114 | 10 | 124 | 1.625e-12 | 8.449e-12 | |
| 11 | Rap1_signaling_pathway_hsa04015 | 11 | 206 | 1.052e-11 | 4.971e-11 | |
| 12 | MAPK_signaling_pathway_hsa04010 | 12 | 295 | 2.656e-11 | 1.151e-10 | |
| 13 | Apoptosis_hsa04210 | 9 | 138 | 1.568e-10 | 6.272e-10 | |
| 14 | Sphingolipid_signaling_pathway_hsa04071 | 8 | 118 | 1.295e-09 | 4.811e-09 | |
| 15 | ErbB_signaling_pathway_hsa04012 | 7 | 85 | 3.816e-09 | 1.323e-08 | |
| 16 | Wnt_signaling_pathway_hsa04310 | 8 | 146 | 7.026e-09 | 2.283e-08 | |
| 17 | mTOR_signaling_pathway_hsa04150 | 8 | 151 | 9.16e-09 | 2.802e-08 | |
| 18 | Hippo_signaling_pathway_hsa04390 | 8 | 154 | 1.069e-08 | 3.089e-08 | |
| 19 | Gap_junction_hsa04540 | 6 | 88 | 1.661e-07 | 4.547e-07 | |
| 20 | TNF_signaling_pathway_hsa04668 | 6 | 108 | 5.62e-07 | 1.461e-06 | |
| 21 | VEGF_signaling_pathway_hsa04370 | 5 | 59 | 6.396e-07 | 1.584e-06 | |
| 22 | NF_kappa_B_signaling_pathway_hsa04064 | 5 | 95 | 6.858e-06 | 1.621e-05 | |
| 23 | Autophagy_animal_hsa04140 | 5 | 128 | 2.919e-05 | 6.6e-05 | |
| 24 | Apelin_signaling_pathway_hsa04371 | 5 | 137 | 4.044e-05 | 8.763e-05 | |
| 25 | Adherens_junction_hsa04520 | 4 | 72 | 4.922e-05 | 0.0001024 | |
| 26 | Phospholipase_D_signaling_pathway_hsa04072 | 5 | 146 | 5.479e-05 | 0.0001096 | |
| 27 | ECM_receptor_interaction_hsa04512 | 4 | 82 | 8.196e-05 | 0.0001579 | |
| 28 | TGF_beta_signaling_pathway_hsa04350 | 4 | 84 | 9.004e-05 | 0.0001672 | |
| 29 | cAMP_signaling_pathway_hsa04024 | 5 | 198 | 0.0002293 | 0.0004111 | |
| 30 | Mitophagy_animal_hsa04137 | 3 | 65 | 0.0008031 | 0.001392 | |
| 31 | Jak_STAT_signaling_pathway_hsa04630 | 4 | 162 | 0.001098 | 0.001841 | |
| 32 | Cell_adhesion_molecules_.CAMs._hsa04514 | 3 | 145 | 0.007816 | 0.0127 | |
| 33 | cGMP_PKG_signaling_pathway_hsa04022 | 3 | 163 | 0.01074 | 0.01693 | |
| 34 | Calcium_signaling_pathway_hsa04020 | 3 | 182 | 0.01444 | 0.02208 | |
| 35 | p53_signaling_pathway_hsa04115 | 2 | 68 | 0.01559 | 0.02316 | |
| 36 | Endocytosis_hsa04144 | 3 | 244 | 0.03096 | 0.04415 | |
| 37 | Phosphatidylinositol_signaling_system_hsa04070 | 2 | 99 | 0.03142 | 0.04415 | |
| 38 | AMPK_signaling_pathway_hsa04152 | 2 | 121 | 0.04523 | 0.06189 | |
| 39 | Tight_junction_hsa04530 | 2 | 170 | 0.08213 | 0.1095 | |
| 40 | Cytokine_cytokine_receptor_interaction_hsa04060 | 2 | 270 | 0.1748 | 0.2164 |
lncRNA-mediated sponge
| Num | lncRNA | miRNAs | miRNAs count | Gene | Sponge regulatory network | lncRNA log2FC | lncRNA pvalue | Gene log2FC | Gene pvalue | lncRNA-gene Pearson correlation |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | HCG11 |
hsa-miR-10b-3p;hsa-miR-1180-3p;hsa-miR-130b-5p;hsa-miR-148b-5p;hsa-miR-16-1-3p;hsa-miR-186-5p;hsa-miR-193a-3p;hsa-miR-221-3p;hsa-miR-362-3p;hsa-miR-421;hsa-miR-455-5p;hsa-miR-532-3p | 12 | ETS1 | Sponge network | -0.781 | 0 | -0.888 | 0 | 0.78 |
| 2 | SNHG1 | hsa-let-7a-3p;hsa-let-7b-3p;hsa-let-7b-5p;hsa-let-7f-1-3p;hsa-miR-130a-3p;hsa-miR-22-3p;hsa-miR-27b-3p;hsa-miR-29a-3p;hsa-miR-29b-3p;hsa-miR-29c-3p;hsa-miR-486-5p | 11 | CCNA2 | Sponge network | 2.013 | 0 | 3.368 | 0 | 0.678 |
| 3 | TMPO-AS1 | hsa-let-7a-3p;hsa-let-7b-3p;hsa-let-7b-5p;hsa-let-7f-1-3p;hsa-miR-130a-3p;hsa-miR-199a-5p;hsa-miR-22-3p;hsa-miR-27b-3p;hsa-miR-29a-3p;hsa-miR-29b-1-5p;hsa-miR-29b-3p;hsa-miR-29c-3p | 12 | CCNA2 | Sponge network | 2.165 | 0 | 3.368 | 0 | 0.67 |
| 4 | RP5-1074L1.4 | hsa-let-7a-3p;hsa-let-7b-3p;hsa-let-7b-5p;hsa-let-7f-1-3p;hsa-miR-130a-3p;hsa-miR-199a-5p;hsa-miR-22-3p;hsa-miR-27b-3p;hsa-miR-29a-3p;hsa-miR-29b-1-5p;hsa-miR-29b-3p;hsa-miR-29c-3p;hsa-miR-374b-5p;hsa-miR-486-5p | 14 | CCNA2 | Sponge network | 2.302 | 0 | 3.368 | 0 | 0.658 |
| 5 | AP001469.9 | hsa-let-7a-3p;hsa-let-7b-3p;hsa-let-7b-5p;hsa-let-7f-1-3p;hsa-miR-130a-3p;hsa-miR-199a-5p;hsa-miR-22-3p;hsa-miR-27b-3p;hsa-miR-29a-3p;hsa-miR-29b-1-5p;hsa-miR-29b-3p;hsa-miR-29c-3p;hsa-miR-486-5p | 13 | CCNA2 | Sponge network | 2.428 | 0 | 3.368 | 0 | 0.619 |
| 6 | DHRS4-AS1 |
hsa-miR-15a-5p;hsa-miR-17-5p;hsa-miR-181a-5p;hsa-miR-181b-5p;hsa-miR-18a-5p;hsa-miR-19a-3p;hsa-miR-19b-3p;hsa-miR-421;hsa-miR-500a-5p;hsa-miR-501-5p | 10 | ARHGAP5 | Sponge network | -0.646 | 0.01829 | -0.391 | 8.0E-5 | 0.615 |
| 7 | MAPKAPK5-AS1 | hsa-let-7a-3p;hsa-let-7b-3p;hsa-let-7b-5p;hsa-let-7f-1-3p;hsa-miR-130a-3p;hsa-miR-22-3p;hsa-miR-27b-3p;hsa-miR-29a-3p;hsa-miR-29c-3p;hsa-miR-486-5p | 10 | CCNA2 | Sponge network | 1.411 | 0 | 3.368 | 0 | 0.604 |
| 8 | PXN-AS1 | hsa-let-7b-3p;hsa-let-7b-5p;hsa-let-7f-1-3p;hsa-miR-130a-3p;hsa-miR-199a-5p;hsa-miR-22-3p;hsa-miR-27b-3p;hsa-miR-29a-3p;hsa-miR-29b-1-5p;hsa-miR-29b-3p;hsa-miR-29c-3p | 11 | CCNA2 | Sponge network | 1.561 | 0 | 3.368 | 0 | 0.591 |
| 9 | RP11-498C9.15 | hsa-let-7a-3p;hsa-let-7b-3p;hsa-let-7b-5p;hsa-let-7f-1-3p;hsa-miR-130a-3p;hsa-miR-22-3p;hsa-miR-27b-3p;hsa-miR-29a-3p;hsa-miR-29b-3p;hsa-miR-29c-3p;hsa-miR-374b-5p | 11 | CCNA2 | Sponge network | 1.487 | 0 | 3.368 | 0 | 0.589 |
| 10 | KB-1572G7.2 | hsa-let-7b-3p;hsa-let-7b-5p;hsa-let-7f-1-3p;hsa-miR-130a-3p;hsa-miR-22-3p;hsa-miR-27b-3p;hsa-miR-29a-3p;hsa-miR-29b-1-5p;hsa-miR-29b-3p;hsa-miR-29c-3p;hsa-miR-374b-5p;hsa-miR-486-5p | 12 | CCNA2 | Sponge network | 2.124 | 0 | 3.368 | 0 | 0.57 |
| 11 | DHRS4-AS1 |
hsa-miR-106b-5p;hsa-miR-1301-3p;hsa-miR-132-3p;hsa-miR-17-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-221-3p;hsa-miR-222-3p;hsa-miR-582-5p;hsa-miR-589-3p | 10 | PIK3R1 | Sponge network | -0.646 | 0.01829 | -0.892 | 0 | 0.557 |
| 12 | RP11-1246C19.1 | hsa-let-7a-3p;hsa-let-7b-3p;hsa-let-7b-5p;hsa-let-7f-1-3p;hsa-miR-130a-3p;hsa-miR-199a-5p;hsa-miR-22-3p;hsa-miR-27b-3p;hsa-miR-29a-3p;hsa-miR-29b-1-5p;hsa-miR-29b-3p;hsa-miR-29c-3p | 12 | CCNA2 | Sponge network | 2.721 | 0 | 3.368 | 0 | 0.556 |
| 13 | GUSBP11 | hsa-let-7b-3p;hsa-let-7b-5p;hsa-let-7f-1-3p;hsa-miR-130a-3p;hsa-miR-22-3p;hsa-miR-27b-3p;hsa-miR-29a-3p;hsa-miR-29b-1-5p;hsa-miR-29b-3p;hsa-miR-29c-3p;hsa-miR-374b-5p;hsa-miR-486-5p | 12 | CCNA2 | Sponge network | 2.066 | 0 | 3.368 | 0 | 0.54 |
| 14 | AC074117.10 | hsa-let-7a-3p;hsa-let-7b-3p;hsa-let-7b-5p;hsa-let-7f-1-3p;hsa-miR-130a-3p;hsa-miR-199a-5p;hsa-miR-22-3p;hsa-miR-27b-3p;hsa-miR-29a-3p;hsa-miR-29c-3p | 10 | CCNA2 | Sponge network | 1.254 | 0 | 3.368 | 0 | 0.537 |
| 15 | TMCC1-AS1 | hsa-let-7a-3p;hsa-let-7b-3p;hsa-let-7b-5p;hsa-let-7f-1-3p;hsa-miR-130a-3p;hsa-miR-199a-5p;hsa-miR-22-3p;hsa-miR-27b-3p;hsa-miR-29a-3p;hsa-miR-29c-3p | 10 | CCNA2 | Sponge network | 2.298 | 0 | 3.368 | 0 | 0.533 |
| 16 | RP4-717I23.3 | hsa-let-7a-3p;hsa-let-7b-3p;hsa-let-7b-5p;hsa-let-7f-1-3p;hsa-miR-130a-3p;hsa-miR-199a-5p;hsa-miR-22-3p;hsa-miR-27b-3p;hsa-miR-29a-3p;hsa-miR-29c-3p;hsa-miR-486-5p | 11 | CCNA2 | Sponge network | 1.867 | 0 | 3.368 | 0 | 0.531 |
| 17 | RP11-434D9.1 | hsa-miR-103a-3p;hsa-miR-106b-5p;hsa-miR-1301-3p;hsa-miR-132-3p;hsa-miR-17-5p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-212-3p;hsa-miR-221-3p;hsa-miR-222-3p;hsa-miR-409-3p;hsa-miR-629-3p | 13 | PIK3R1 | Sponge network | -2.913 | 0 | -0.892 | 0 | 0.525 |
| 18 | PRKAR2A-AS1 | hsa-let-7a-3p;hsa-let-7b-3p;hsa-let-7b-5p;hsa-let-7f-1-3p;hsa-miR-130a-3p;hsa-miR-199a-5p;hsa-miR-22-3p;hsa-miR-27b-3p;hsa-miR-29a-3p;hsa-miR-29b-3p;hsa-miR-29c-3p | 11 | CCNA2 | Sponge network | 2.366 | 0 | 3.368 | 0 | 0.52 |
| 19 | LINC00261 |
hsa-miR-106b-5p;hsa-miR-1301-3p;hsa-miR-132-3p;hsa-miR-15b-5p;hsa-miR-188-5p;hsa-miR-21-5p;hsa-miR-212-3p;hsa-miR-221-3p;hsa-miR-222-3p;hsa-miR-324-3p;hsa-miR-330-3p;hsa-miR-589-3p;hsa-miR-629-3p | 13 | PIK3R1 | Sponge network | -1.194 | 0 | -0.892 | 0 | 0.513 |
| 20 | RP11-111M22.4 | hsa-let-7a-3p;hsa-let-7b-3p;hsa-let-7b-5p;hsa-let-7f-1-3p;hsa-miR-130a-3p;hsa-miR-199a-5p;hsa-miR-22-3p;hsa-miR-27b-3p;hsa-miR-29b-1-5p;hsa-miR-374b-5p | 10 | CCNA2 | Sponge network | 3.722 | 0 | 3.368 | 0 | 0.509 |
| 21 | GAS5 | hsa-let-7a-3p;hsa-let-7b-3p;hsa-let-7b-5p;hsa-let-7f-1-3p;hsa-miR-130a-3p;hsa-miR-22-3p;hsa-miR-27b-3p;hsa-miR-29a-3p;hsa-miR-29b-1-5p;hsa-miR-29c-3p;hsa-miR-374b-5p | 11 | CCNA2 | Sponge network | 1.966 | 0 | 3.368 | 0 | 0.506 |
| 22 | NPSR1-AS1 | hsa-let-7a-3p;hsa-let-7b-3p;hsa-let-7b-5p;hsa-let-7f-1-3p;hsa-miR-130a-3p;hsa-miR-199a-5p;hsa-miR-22-3p;hsa-miR-27b-3p;hsa-miR-29a-3p;hsa-miR-29b-1-5p;hsa-miR-29b-3p;hsa-miR-29c-3p;hsa-miR-486-5p | 13 | CCNA2 | Sponge network | 5.28 | 0 | 3.368 | 0 | 0.505 |
| 23 | CTD-2561J22.5 | hsa-let-7b-3p;hsa-let-7b-5p;hsa-let-7f-1-3p;hsa-miR-130a-3p;hsa-miR-22-3p;hsa-miR-27b-3p;hsa-miR-29a-3p;hsa-miR-29b-1-5p;hsa-miR-29b-3p;hsa-miR-29c-3p;hsa-miR-486-5p | 11 | CCNA2 | Sponge network | 2.129 | 0 | 3.368 | 0 | 0.495 |
| 24 | SNHG7 | hsa-let-7a-3p;hsa-let-7b-3p;hsa-let-7b-5p;hsa-let-7f-1-3p;hsa-miR-130a-3p;hsa-miR-22-3p;hsa-miR-27b-3p;hsa-miR-29a-3p;hsa-miR-29c-3p;hsa-miR-486-5p | 10 | CCNA2 | Sponge network | 2.077 | 0 | 3.368 | 0 | 0.494 |
| 25 | RP11-513G11.3 | hsa-miR-103a-3p;hsa-miR-106b-5p;hsa-miR-1301-3p;hsa-miR-132-3p;hsa-miR-17-5p;hsa-miR-21-5p;hsa-miR-212-3p;hsa-miR-221-3p;hsa-miR-222-3p;hsa-miR-93-5p | 10 | PIK3R1 | Sponge network | -2.342 | 5.0E-5 | -0.892 | 0 | 0.492 |
| 26 | CTC-338M12.4 | hsa-let-7a-3p;hsa-let-7b-3p;hsa-let-7b-5p;hsa-let-7f-1-3p;hsa-miR-130a-3p;hsa-miR-199a-5p;hsa-miR-22-3p;hsa-miR-27b-3p;hsa-miR-29a-3p;hsa-miR-29c-3p | 10 | CCNA2 | Sponge network | 1.926 | 0 | 3.368 | 0 | 0.491 |
| 27 | RP11-12A2.3 |
hsa-miR-103a-3p;hsa-miR-106b-5p;hsa-miR-1301-3p;hsa-miR-132-3p;hsa-miR-17-5p;hsa-miR-185-5p;hsa-miR-188-5p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-212-3p;hsa-miR-221-3p;hsa-miR-222-3p;hsa-miR-93-5p | 14 | PIK3R1 | Sponge network | -4.779 | 0 | -0.892 | 0 | 0.489 |
| 28 | RP11-216L13.19 | hsa-let-7a-3p;hsa-let-7b-3p;hsa-let-7b-5p;hsa-let-7f-1-3p;hsa-miR-130a-3p;hsa-miR-199a-5p;hsa-miR-22-3p;hsa-miR-27b-3p;hsa-miR-29a-3p;hsa-miR-29c-3p | 10 | CCNA2 | Sponge network | 2.404 | 0 | 3.368 | 0 | 0.482 |
| 29 | RP11-328N19.1 | hsa-let-7a-3p;hsa-let-7b-3p;hsa-let-7b-5p;hsa-let-7f-1-3p;hsa-miR-130a-3p;hsa-miR-199a-5p;hsa-miR-22-3p;hsa-miR-27b-3p;hsa-miR-29a-3p;hsa-miR-29b-3p;hsa-miR-29c-3p | 11 | CCNA2 | Sponge network | 7.657 | 0 | 3.368 | 0 | 0.48 |
| 30 | AC098820.3 | hsa-let-7a-3p;hsa-let-7b-3p;hsa-let-7f-1-3p;hsa-miR-130a-3p;hsa-miR-199a-5p;hsa-miR-22-3p;hsa-miR-29a-3p;hsa-miR-29b-1-5p;hsa-miR-29b-3p;hsa-miR-29c-3p | 10 | CCNA2 | Sponge network | 1.898 | 0 | 3.368 | 0 | 0.475 |
| 31 | RAB30-AS1 | hsa-let-7a-3p;hsa-let-7b-3p;hsa-let-7b-5p;hsa-let-7f-1-3p;hsa-miR-130a-3p;hsa-miR-22-3p;hsa-miR-29a-3p;hsa-miR-29b-3p;hsa-miR-29c-3p;hsa-miR-486-5p | 10 | CCNA2 | Sponge network | 1.001 | 0 | 3.368 | 0 | 0.475 |
| 32 | AC005154.6 | hsa-let-7a-3p;hsa-let-7b-3p;hsa-let-7b-5p;hsa-let-7f-1-3p;hsa-miR-130a-3p;hsa-miR-22-3p;hsa-miR-27b-3p;hsa-miR-29a-3p;hsa-miR-29c-3p;hsa-miR-486-5p | 10 | CCNA2 | Sponge network | 1.75 | 0 | 3.368 | 0 | 0.473 |
| 33 | LINC01018 |
hsa-miR-103a-3p;hsa-miR-106b-5p;hsa-miR-1301-3p;hsa-miR-132-3p;hsa-miR-17-5p;hsa-miR-188-5p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-212-3p;hsa-miR-221-3p;hsa-miR-222-3p;hsa-miR-324-3p;hsa-miR-338-5p;hsa-miR-409-3p;hsa-miR-589-3p;hsa-miR-629-3p;hsa-miR-93-5p | 18 | PIK3R1 | Sponge network | -3.231 | 0 | -0.892 | 0 | 0.472 |
| 34 | HCG11 |
hsa-miR-106b-5p;hsa-miR-130b-3p;hsa-miR-17-5p;hsa-miR-18a-5p;hsa-miR-19a-3p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-301a-3p;hsa-miR-501-3p;hsa-miR-93-5p | 11 | TGFBR2 | Sponge network | -0.781 | 0 | -0.523 | 3.0E-5 | 0.472 |
| 35 | RP11-727A23.5 | hsa-let-7a-3p;hsa-let-7b-3p;hsa-let-7b-5p;hsa-let-7f-1-3p;hsa-miR-130a-3p;hsa-miR-199a-5p;hsa-miR-22-3p;hsa-miR-27b-3p;hsa-miR-29a-3p;hsa-miR-29b-1-5p;hsa-miR-29c-3p;hsa-miR-486-5p | 12 | CCNA2 | Sponge network | 1.435 | 0 | 3.368 | 0 | 0.468 |
| 36 | RP5-1120P11.1 | hsa-let-7b-3p;hsa-let-7b-5p;hsa-let-7f-1-3p;hsa-miR-130a-3p;hsa-miR-199a-5p;hsa-miR-22-3p;hsa-miR-27b-3p;hsa-miR-29a-3p;hsa-miR-29b-1-5p;hsa-miR-29b-3p;hsa-miR-29c-3p;hsa-miR-486-5p | 12 | CCNA2 | Sponge network | 3.942 | 0 | 3.368 | 0 | 0.465 |
| 37 | RP11-37B2.1 | hsa-let-7a-3p;hsa-let-7b-3p;hsa-let-7b-5p;hsa-let-7f-1-3p;hsa-miR-130a-3p;hsa-miR-22-3p;hsa-miR-27b-3p;hsa-miR-29a-3p;hsa-miR-29c-3p;hsa-miR-486-5p | 10 | CCNA2 | Sponge network | 1.504 | 0 | 3.368 | 0 | 0.459 |
| 38 | LINC01004 | hsa-let-7a-3p;hsa-let-7b-3p;hsa-let-7b-5p;hsa-let-7f-1-3p;hsa-miR-130a-3p;hsa-miR-22-3p;hsa-miR-27b-3p;hsa-miR-29a-3p;hsa-miR-29c-3p;hsa-miR-374b-5p | 10 | CCNA2 | Sponge network | 2.116 | 0 | 3.368 | 0 | 0.458 |
| 39 | HCG18 | hsa-let-7b-3p;hsa-let-7b-5p;hsa-let-7f-1-3p;hsa-miR-130a-3p;hsa-miR-22-3p;hsa-miR-27b-3p;hsa-miR-29a-3p;hsa-miR-29b-3p;hsa-miR-29c-3p;hsa-miR-486-5p | 10 | CCNA2 | Sponge network | 1.42 | 0 | 3.368 | 0 | 0.457 |
| 40 | TEX41 | hsa-let-7b-3p;hsa-let-7b-5p;hsa-let-7f-1-3p;hsa-miR-130a-3p;hsa-miR-199a-5p;hsa-miR-22-3p;hsa-miR-27b-3p;hsa-miR-29a-3p;hsa-miR-29b-3p;hsa-miR-29c-3p;hsa-miR-486-5p | 11 | CCNA2 | Sponge network | 3.293 | 0 | 3.368 | 0 | 0.452 |
| 41 | HOTTIP | hsa-let-7b-3p;hsa-let-7b-5p;hsa-let-7f-1-3p;hsa-miR-130a-3p;hsa-miR-199a-5p;hsa-miR-22-3p;hsa-miR-27b-3p;hsa-miR-29a-3p;hsa-miR-29b-3p;hsa-miR-29c-3p | 10 | CCNA2 | Sponge network | 7.501 | 0 | 3.368 | 0 | 0.452 |
| 42 | RHPN1-AS1 | hsa-let-7a-3p;hsa-let-7b-3p;hsa-let-7b-5p;hsa-let-7f-1-3p;hsa-miR-130a-3p;hsa-miR-199a-5p;hsa-miR-22-3p;hsa-miR-27b-3p;hsa-miR-29a-3p;hsa-miR-29c-3p;hsa-miR-486-5p | 11 | CCNA2 | Sponge network | 1.895 | 0 | 3.368 | 0 | 0.451 |
| 43 | LDLRAD4-AS1 |
hsa-miR-103a-3p;hsa-miR-106b-5p;hsa-miR-1301-3p;hsa-miR-132-3p;hsa-miR-17-5p;hsa-miR-188-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-212-3p;hsa-miR-221-3p;hsa-miR-222-3p;hsa-miR-589-3p;hsa-miR-93-5p | 13 | PIK3R1 | Sponge network | -3.366 | 0 | -0.892 | 0 | 0.45 |
| 44 | ERVK3-1 | hsa-let-7b-3p;hsa-let-7b-5p;hsa-let-7f-1-3p;hsa-miR-130a-3p;hsa-miR-22-3p;hsa-miR-27b-3p;hsa-miR-29a-3p;hsa-miR-29c-3p;hsa-miR-374b-5p;hsa-miR-486-5p | 10 | CCNA2 | Sponge network | 1.328 | 0 | 3.368 | 0 | 0.448 |
| 45 | HOXA11-AS | hsa-let-7b-3p;hsa-let-7b-5p;hsa-let-7f-1-3p;hsa-miR-130a-3p;hsa-miR-199a-5p;hsa-miR-22-3p;hsa-miR-27b-3p;hsa-miR-29a-3p;hsa-miR-29b-3p;hsa-miR-29c-3p | 10 | CCNA2 | Sponge network | 6.056 | 0 | 3.368 | 0 | 0.448 |
| 46 | AC005550.3 |
hsa-miR-15b-3p;hsa-miR-181a-5p;hsa-miR-181b-5p;hsa-miR-19b-1-5p;hsa-miR-20a-3p;hsa-miR-21-5p;hsa-miR-215-5p;hsa-miR-217;hsa-miR-222-3p;hsa-miR-92a-3p | 10 | FGF2 | Sponge network | -2.571 | 0.00132 | -1.086 | 0.00032 | 0.448 |
| 47 | AC159540.1 | hsa-let-7b-3p;hsa-miR-130a-3p;hsa-miR-22-3p;hsa-miR-27b-3p;hsa-miR-29a-3p;hsa-miR-29b-1-5p;hsa-miR-29b-3p;hsa-miR-29c-3p;hsa-miR-374b-5p;hsa-miR-486-5p | 10 | CCNA2 | Sponge network | 2.112 | 0 | 3.368 | 0 | 0.442 |
| 48 | RP11-458D21.1 | hsa-let-7a-3p;hsa-let-7b-3p;hsa-let-7b-5p;hsa-let-7f-1-3p;hsa-miR-130a-3p;hsa-miR-199a-5p;hsa-miR-22-3p;hsa-miR-27b-3p;hsa-miR-29a-3p;hsa-miR-29b-1-5p;hsa-miR-29b-3p;hsa-miR-29c-3p | 12 | CCNA2 | Sponge network | 1.399 | 0 | 3.368 | 0 | 0.439 |
| 49 | AC062029.1 | hsa-let-7a-3p;hsa-let-7b-3p;hsa-let-7b-5p;hsa-let-7f-1-3p;hsa-miR-130a-3p;hsa-miR-199a-5p;hsa-miR-22-3p;hsa-miR-27b-3p;hsa-miR-29a-3p;hsa-miR-29c-3p | 10 | CCNA2 | Sponge network | 1.067 | 0 | 3.368 | 0 | 0.435 |
| 50 | RP11-758M4.4 | hsa-let-7a-3p;hsa-let-7b-3p;hsa-let-7b-5p;hsa-let-7f-1-3p;hsa-miR-130a-3p;hsa-miR-199a-5p;hsa-miR-22-3p;hsa-miR-27b-3p;hsa-miR-29a-3p;hsa-miR-29b-3p;hsa-miR-29c-3p | 11 | CCNA2 | Sponge network | 3.598 | 0 | 3.368 | 0 | 0.433 |
| 51 | MAGI2-AS3 |
hsa-miR-106b-5p;hsa-miR-130b-3p;hsa-miR-17-5p;hsa-miR-18a-5p;hsa-miR-19a-3p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-301a-3p;hsa-miR-454-3p;hsa-miR-92a-3p;hsa-miR-93-5p | 12 | TGFBR2 | Sponge network | -1.801 | 0 | -0.523 | 3.0E-5 | 0.428 |
| 52 | RP11-540A21.2 | hsa-let-7a-3p;hsa-let-7b-3p;hsa-let-7b-5p;hsa-let-7f-1-3p;hsa-miR-130a-3p;hsa-miR-199a-5p;hsa-miR-22-3p;hsa-miR-27b-3p;hsa-miR-29a-3p;hsa-miR-29b-1-5p;hsa-miR-29b-3p;hsa-miR-29c-3p;hsa-miR-486-5p | 13 | CCNA2 | Sponge network | 1.758 | 0 | 3.368 | 0 | 0.425 |
| 53 | LINC00668 | hsa-let-7a-3p;hsa-let-7b-3p;hsa-let-7b-5p;hsa-let-7f-1-3p;hsa-miR-130a-3p;hsa-miR-199a-5p;hsa-miR-22-3p;hsa-miR-27b-3p;hsa-miR-29a-3p;hsa-miR-29c-3p | 10 | CCNA2 | Sponge network | 3.665 | 0 | 3.368 | 0 | 0.422 |
| 54 | PSMD5-AS1 | hsa-let-7b-3p;hsa-let-7b-5p;hsa-let-7f-1-3p;hsa-miR-130a-3p;hsa-miR-22-3p;hsa-miR-27b-3p;hsa-miR-29a-3p;hsa-miR-29b-3p;hsa-miR-29c-3p;hsa-miR-486-5p | 10 | CCNA2 | Sponge network | 1.538 | 0 | 3.368 | 0 | 0.42 |
| 55 | RP11-119D9.1 |
hsa-miR-106b-5p;hsa-miR-1301-3p;hsa-miR-132-3p;hsa-miR-188-5p;hsa-miR-200c-3p;hsa-miR-21-5p;hsa-miR-212-3p;hsa-miR-221-3p;hsa-miR-222-3p;hsa-miR-629-3p;hsa-miR-93-5p | 11 | PIK3R1 | Sponge network | -2.765 | 0 | -0.892 | 0 | 0.418 |
| 56 | RP11-166D19.1 |
hsa-miR-1180-3p;hsa-miR-148b-5p;hsa-miR-16-1-3p;hsa-miR-186-5p;hsa-miR-193a-3p;hsa-miR-222-3p;hsa-miR-421;hsa-miR-532-3p;hsa-miR-590-5p;hsa-miR-940 | 10 | ETS1 | Sponge network | -0.244 | 0.28835 | -0.888 | 0 | 0.417 |
| 57 | MAGI2-AS3 |
hsa-miR-10b-3p;hsa-miR-1180-3p;hsa-miR-193a-3p;hsa-miR-221-3p;hsa-miR-222-3p;hsa-miR-362-3p;hsa-miR-421;hsa-miR-455-5p;hsa-miR-501-5p;hsa-miR-532-3p;hsa-miR-660-5p;hsa-miR-769-5p;hsa-miR-940 | 13 | ETS1 | Sponge network | -1.801 | 0 | -0.888 | 0 | 0.413 |
| 58 | AC012146.7 | hsa-let-7a-3p;hsa-let-7b-3p;hsa-let-7b-5p;hsa-let-7f-1-3p;hsa-miR-130a-3p;hsa-miR-199a-5p;hsa-miR-22-3p;hsa-miR-27b-3p;hsa-miR-29a-3p;hsa-miR-29b-3p;hsa-miR-29c-3p | 11 | CCNA2 | Sponge network | 1.709 | 0 | 3.368 | 0 | 0.413 |
| 59 | CTBP1-AS2 | hsa-let-7a-3p;hsa-let-7b-3p;hsa-let-7b-5p;hsa-let-7f-1-3p;hsa-miR-130a-3p;hsa-miR-22-3p;hsa-miR-27b-3p;hsa-miR-29a-3p;hsa-miR-29b-3p;hsa-miR-29c-3p;hsa-miR-486-5p | 11 | CCNA2 | Sponge network | 1.419 | 0 | 3.368 | 0 | 0.406 |
| 60 | CRNDE | hsa-let-7a-3p;hsa-let-7b-3p;hsa-let-7b-5p;hsa-miR-130a-3p;hsa-miR-199a-5p;hsa-miR-22-3p;hsa-miR-27b-3p;hsa-miR-29a-3p;hsa-miR-29b-3p;hsa-miR-29c-3p;hsa-miR-486-5p | 11 | CCNA2 | Sponge network | 3.271 | 0 | 3.368 | 0 | 0.404 |
| 61 | RP11-290F5.1 | hsa-miR-103a-3p;hsa-miR-106b-5p;hsa-miR-1301-3p;hsa-miR-132-3p;hsa-miR-17-5p;hsa-miR-188-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-212-3p;hsa-miR-221-3p;hsa-miR-222-3p;hsa-miR-324-3p;hsa-miR-493-5p | 13 | PIK3R1 | Sponge network | -1.679 | 5.0E-5 | -0.892 | 0 | 0.402 |
| 62 | GS1-124K5.11 | hsa-let-7a-3p;hsa-let-7b-3p;hsa-let-7b-5p;hsa-let-7f-1-3p;hsa-miR-130a-3p;hsa-miR-22-3p;hsa-miR-27b-3p;hsa-miR-29a-3p;hsa-miR-29c-3p;hsa-miR-486-5p | 10 | CCNA2 | Sponge network | 1.5 | 0 | 3.368 | 0 | 0.402 |
| 63 | DNAJC3-AS1 | hsa-let-7a-3p;hsa-let-7b-3p;hsa-let-7f-1-3p;hsa-miR-130a-3p;hsa-miR-199a-5p;hsa-miR-22-3p;hsa-miR-27b-3p;hsa-miR-29a-3p;hsa-miR-29b-3p;hsa-miR-29c-3p;hsa-miR-374b-5p | 11 | CCNA2 | Sponge network | 0.905 | 0 | 3.368 | 0 | 0.395 |
| 64 | KB-431C1.4 | hsa-let-7a-3p;hsa-let-7b-3p;hsa-let-7b-5p;hsa-let-7f-1-3p;hsa-miR-130a-3p;hsa-miR-199a-5p;hsa-miR-22-3p;hsa-miR-27b-3p;hsa-miR-29a-3p;hsa-miR-29c-3p | 10 | CCNA2 | Sponge network | 1.573 | 0 | 3.368 | 0 | 0.39 |
| 65 | DHRS4-AS1 |
hsa-miR-1180-3p;hsa-miR-148b-5p;hsa-miR-221-3p;hsa-miR-222-3p;hsa-miR-30d-3p;hsa-miR-421;hsa-miR-501-5p;hsa-miR-502-5p;hsa-miR-660-5p;hsa-miR-769-5p | 10 | ETS1 | Sponge network | -0.646 | 0.01829 | -0.888 | 0 | 0.384 |
| 66 | RP11-115J16.1 | hsa-miR-103a-3p;hsa-miR-1301-3p;hsa-miR-132-3p;hsa-miR-185-5p;hsa-miR-21-5p;hsa-miR-212-3p;hsa-miR-221-3p;hsa-miR-222-3p;hsa-miR-324-3p;hsa-miR-338-5p;hsa-miR-589-3p;hsa-miR-93-5p | 12 | PIK3R1 | Sponge network | -2.038 | 7.0E-5 | -0.892 | 0 | 0.382 |
| 67 | CTD-2228K2.7 | hsa-let-7a-3p;hsa-let-7b-3p;hsa-let-7b-5p;hsa-miR-130a-3p;hsa-miR-22-3p;hsa-miR-27b-3p;hsa-miR-29a-3p;hsa-miR-29b-3p;hsa-miR-29c-3p;hsa-miR-374b-5p;hsa-miR-486-5p | 11 | CCNA2 | Sponge network | 2.28 | 0 | 3.368 | 0 | 0.379 |
| 68 | RP4-601P9.2 | hsa-miR-15b-3p;hsa-miR-15b-5p;hsa-miR-16-2-3p;hsa-miR-181a-5p;hsa-miR-181b-5p;hsa-miR-200c-3p;hsa-miR-21-3p;hsa-miR-21-5p;hsa-miR-217;hsa-miR-335-3p | 10 | FGF2 | Sponge network | -1.638 | 0.0053 | -1.086 | 0.00032 | 0.376 |
| 69 | AL133493.2 | hsa-let-7a-3p;hsa-let-7b-3p;hsa-let-7b-5p;hsa-let-7f-1-3p;hsa-miR-199a-5p;hsa-miR-22-3p;hsa-miR-27b-3p;hsa-miR-29a-3p;hsa-miR-29b-3p;hsa-miR-29c-3p;hsa-miR-486-5p | 11 | CCNA2 | Sponge network | 2.464 | 0.00305 | 3.368 | 0 | 0.372 |
| 70 | LINC00238 | hsa-miR-106b-5p;hsa-miR-1301-3p;hsa-miR-132-3p;hsa-miR-17-5p;hsa-miR-185-5p;hsa-miR-188-5p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-212-3p;hsa-miR-221-3p;hsa-miR-222-3p;hsa-miR-629-3p | 12 | PIK3R1 | Sponge network | -4.997 | 0 | -0.892 | 0 | 0.369 |
| 71 | RP5-1165K10.2 | hsa-let-7a-3p;hsa-let-7b-3p;hsa-let-7b-5p;hsa-let-7f-1-3p;hsa-miR-130a-3p;hsa-miR-22-3p;hsa-miR-27b-3p;hsa-miR-29a-3p;hsa-miR-29b-3p;hsa-miR-29c-3p | 10 | CCNA2 | Sponge network | 1.401 | 0 | 3.368 | 0 | 0.367 |
| 72 | RP11-89K21.1 | hsa-let-7b-3p;hsa-miR-130a-3p;hsa-miR-22-3p;hsa-miR-27b-3p;hsa-miR-29a-3p;hsa-miR-29b-1-5p;hsa-miR-29b-3p;hsa-miR-29c-3p;hsa-miR-374b-5p;hsa-miR-486-5p | 10 | CCNA2 | Sponge network | 4.915 | 0 | 3.368 | 0 | 0.364 |
| 73 | NUTM2A-AS1 | hsa-let-7a-3p;hsa-let-7b-3p;hsa-let-7b-5p;hsa-let-7f-1-3p;hsa-miR-22-3p;hsa-miR-27b-3p;hsa-miR-29a-3p;hsa-miR-29b-1-5p;hsa-miR-29b-3p;hsa-miR-29c-3p;hsa-miR-374b-5p;hsa-miR-486-5p | 12 | CCNA2 | Sponge network | 0.788 | 0 | 3.368 | 0 | 0.358 |
| 74 | AC004862.6 | hsa-miR-106b-5p;hsa-miR-1301-3p;hsa-miR-132-3p;hsa-miR-17-5p;hsa-miR-188-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-212-3p;hsa-miR-221-3p;hsa-miR-222-3p;hsa-miR-589-3p;hsa-miR-629-3p;hsa-miR-93-5p | 13 | PIK3R1 | Sponge network | -2.202 | 0.00081 | -0.892 | 0 | 0.357 |
| 75 | MAGI2-AS3 |
hsa-miR-103a-3p;hsa-miR-15b-3p;hsa-miR-15b-5p;hsa-miR-19b-1-5p;hsa-miR-20a-3p;hsa-miR-21-5p;hsa-miR-222-3p;hsa-miR-452-5p;hsa-miR-589-3p;hsa-miR-92a-3p;hsa-miR-93-3p | 11 | FGF2 | Sponge network | -1.801 | 0 | -1.086 | 0.00032 | 0.356 |
| 76 | LINC00648 | hsa-let-7a-3p;hsa-let-7b-3p;hsa-let-7b-5p;hsa-let-7f-1-3p;hsa-miR-130a-3p;hsa-miR-199a-5p;hsa-miR-22-3p;hsa-miR-27b-3p;hsa-miR-29a-3p;hsa-miR-29b-3p;hsa-miR-29c-3p | 11 | CCNA2 | Sponge network | 3.27 | 0.00013 | 3.368 | 0 | 0.351 |
| 77 | DNM1P35 | hsa-let-7a-3p;hsa-let-7b-3p;hsa-let-7b-5p;hsa-let-7f-1-3p;hsa-miR-130a-3p;hsa-miR-199a-5p;hsa-miR-22-3p;hsa-miR-27b-3p;hsa-miR-29a-3p;hsa-miR-29b-1-5p;hsa-miR-29b-3p;hsa-miR-29c-3p | 12 | CCNA2 | Sponge network | 1.581 | 0 | 3.368 | 0 | 0.351 |
| 78 | POLR2J4 | hsa-let-7a-3p;hsa-let-7b-3p;hsa-let-7b-5p;hsa-let-7f-1-3p;hsa-miR-130a-3p;hsa-miR-22-3p;hsa-miR-27b-3p;hsa-miR-29a-3p;hsa-miR-29b-3p;hsa-miR-29c-3p | 10 | CCNA2 | Sponge network | 1.386 | 0 | 3.368 | 0 | 0.348 |
| 79 | RP11-341N2.1 | hsa-let-7a-3p;hsa-let-7b-3p;hsa-let-7f-1-3p;hsa-miR-130a-3p;hsa-miR-199a-5p;hsa-miR-22-3p;hsa-miR-27b-3p;hsa-miR-29a-3p;hsa-miR-29b-1-5p;hsa-miR-29b-3p;hsa-miR-29c-3p;hsa-miR-486-5p | 12 | CCNA2 | Sponge network | 3.431 | 0 | 3.368 | 0 | 0.347 |
| 80 | RP11-250B2.6 | hsa-miR-103a-3p;hsa-miR-106b-5p;hsa-miR-1301-3p;hsa-miR-132-3p;hsa-miR-17-5p;hsa-miR-188-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-212-3p;hsa-miR-221-3p;hsa-miR-222-3p;hsa-miR-93-5p | 12 | PIK3R1 | Sponge network | -0.98 | 2.0E-5 | -0.892 | 0 | 0.342 |
| 81 | AP000473.5 | hsa-miR-106b-5p;hsa-miR-1301-3p;hsa-miR-132-3p;hsa-miR-17-5p;hsa-miR-185-5p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-212-3p;hsa-miR-221-3p;hsa-miR-222-3p;hsa-miR-338-5p | 11 | PIK3R1 | Sponge network | -1.157 | 0.00884 | -0.892 | 0 | 0.341 |
| 82 | TMEM161B-AS1 | hsa-let-7a-3p;hsa-let-7b-3p;hsa-let-7b-5p;hsa-let-7f-1-3p;hsa-miR-130a-3p;hsa-miR-199a-5p;hsa-miR-22-3p;hsa-miR-27b-3p;hsa-miR-29c-3p;hsa-miR-486-5p | 10 | CCNA2 | Sponge network | 1.593 | 0 | 3.368 | 0 | 0.336 |
| 83 | RP11-963H4.3 | hsa-miR-106b-5p;hsa-miR-15b-5p;hsa-miR-17-5p;hsa-miR-21-5p;hsa-miR-221-3p;hsa-miR-222-3p;hsa-miR-324-3p;hsa-miR-590-5p;hsa-miR-629-3p;hsa-miR-93-5p | 10 | PIK3R1 | Sponge network | -1.857 | 0.00116 | -0.892 | 0 | 0.328 |
| 84 | LINC00624 | hsa-let-7b-3p;hsa-miR-130a-3p;hsa-miR-199a-5p;hsa-miR-22-3p;hsa-miR-27b-3p;hsa-miR-29a-3p;hsa-miR-29b-1-5p;hsa-miR-29b-3p;hsa-miR-29c-3p;hsa-miR-486-5p | 10 | CCNA2 | Sponge network | 3.71 | 0 | 3.368 | 0 | 0.324 |
| 85 | RP11-407B7.1 | hsa-miR-106b-5p;hsa-miR-1301-3p;hsa-miR-132-3p;hsa-miR-188-5p;hsa-miR-21-5p;hsa-miR-212-3p;hsa-miR-221-3p;hsa-miR-222-3p;hsa-miR-324-3p;hsa-miR-338-5p;hsa-miR-582-5p;hsa-miR-629-3p;hsa-miR-93-5p | 13 | PIK3R1 | Sponge network | -0.818 | 0.00584 | -0.892 | 0 | 0.324 |
| 86 | RP11-166D19.1 |
hsa-miR-106b-5p;hsa-miR-130b-3p;hsa-miR-17-5p;hsa-miR-18a-5p;hsa-miR-19a-3p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-301a-3p;hsa-miR-590-5p;hsa-miR-92a-3p | 11 | TGFBR2 | Sponge network | -0.244 | 0.28835 | -0.523 | 3.0E-5 | 0.324 |
| 87 | LINC00864 | hsa-miR-103a-3p;hsa-miR-106b-5p;hsa-miR-1301-3p;hsa-miR-132-3p;hsa-miR-15b-5p;hsa-miR-185-5p;hsa-miR-21-5p;hsa-miR-221-3p;hsa-miR-222-3p;hsa-miR-629-3p | 10 | PIK3R1 | Sponge network | -3.954 | 0 | -0.892 | 0 | 0.322 |
| 88 | RP11-166D19.1 |
hsa-miR-103a-3p;hsa-miR-106b-5p;hsa-miR-1301-3p;hsa-miR-15b-5p;hsa-miR-17-5p;hsa-miR-185-5p;hsa-miR-188-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-222-3p;hsa-miR-324-3p;hsa-miR-589-3p;hsa-miR-590-5p;hsa-miR-629-3p | 14 | PIK3R1 | Sponge network | -0.244 | 0.28835 | -0.892 | 0 | 0.32 |
| 89 | AC084219.4 | hsa-let-7a-3p;hsa-let-7b-3p;hsa-let-7b-5p;hsa-let-7f-1-3p;hsa-miR-130a-3p;hsa-miR-199a-5p;hsa-miR-27b-3p;hsa-miR-29a-3p;hsa-miR-29b-1-5p;hsa-miR-29b-3p;hsa-miR-29c-3p | 11 | CCNA2 | Sponge network | 3.914 | 0 | 3.368 | 0 | 0.318 |
| 90 | TAPT1-AS1 | hsa-let-7a-3p;hsa-let-7b-3p;hsa-let-7b-5p;hsa-let-7f-1-3p;hsa-miR-130a-3p;hsa-miR-22-3p;hsa-miR-27b-3p;hsa-miR-29a-3p;hsa-miR-29c-3p;hsa-miR-486-5p | 10 | CCNA2 | Sponge network | 1.165 | 0 | 3.368 | 0 | 0.316 |
| 91 | RP1-179N16.6 | hsa-let-7a-3p;hsa-let-7b-3p;hsa-let-7b-5p;hsa-let-7f-1-3p;hsa-miR-130a-3p;hsa-miR-199a-5p;hsa-miR-22-3p;hsa-miR-27b-3p;hsa-miR-29b-1-5p;hsa-miR-486-5p | 10 | CCNA2 | Sponge network | 1.955 | 0 | 3.368 | 0 | 0.311 |
| 92 | RP11-166D19.1 |
hsa-miR-103a-3p;hsa-miR-15b-3p;hsa-miR-15b-5p;hsa-miR-16-2-3p;hsa-miR-19b-1-5p;hsa-miR-20a-3p;hsa-miR-21-5p;hsa-miR-222-3p;hsa-miR-589-3p;hsa-miR-590-5p;hsa-miR-92a-3p;hsa-miR-93-3p | 12 | FGF2 | Sponge network | -0.244 | 0.28835 | -1.086 | 0.00032 | 0.306 |
| 93 | AC073283.4 | hsa-let-7a-3p;hsa-let-7b-3p;hsa-let-7b-5p;hsa-let-7f-1-3p;hsa-miR-130a-3p;hsa-miR-22-3p;hsa-miR-27b-3p;hsa-miR-29a-3p;hsa-miR-29b-3p;hsa-miR-29c-3p | 10 | CCNA2 | Sponge network | 1.514 | 0 | 3.368 | 0 | 0.301 |
| 94 | LINC00885 | hsa-miR-106b-5p;hsa-miR-1301-3p;hsa-miR-17-5p;hsa-miR-185-5p;hsa-miR-188-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-221-3p;hsa-miR-222-3p;hsa-miR-324-3p | 10 | PIK3R1 | Sponge network | -4.686 | 0 | -0.892 | 0 | 0.3 |
| 95 | NOP14-AS1 | hsa-let-7a-3p;hsa-let-7b-3p;hsa-let-7b-5p;hsa-let-7f-1-3p;hsa-miR-130a-3p;hsa-miR-22-3p;hsa-miR-27b-3p;hsa-miR-29a-3p;hsa-miR-29c-3p;hsa-miR-486-5p | 10 | CCNA2 | Sponge network | 1.279 | 0 | 3.368 | 0 | 0.295 |
| 96 | U91328.19 | hsa-let-7b-3p;hsa-let-7b-5p;hsa-let-7f-1-3p;hsa-miR-130a-3p;hsa-miR-199a-5p;hsa-miR-22-3p;hsa-miR-27b-3p;hsa-miR-29a-3p;hsa-miR-29b-3p;hsa-miR-29c-3p | 10 | CCNA2 | Sponge network | 1.281 | 0 | 3.368 | 0 | 0.294 |
| 97 | MAGI2-AS3 |
hsa-miR-103a-3p;hsa-miR-106b-5p;hsa-miR-1301-3p;hsa-miR-15b-5p;hsa-miR-17-5p;hsa-miR-188-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-221-3p;hsa-miR-222-3p;hsa-miR-589-3p;hsa-miR-629-3p;hsa-miR-93-5p | 13 | PIK3R1 | Sponge network | -1.801 | 0 | -0.892 | 0 | 0.294 |
| 98 | CASC2 |
hsa-miR-103a-3p;hsa-miR-155-5p;hsa-miR-15a-5p;hsa-miR-16-1-3p;hsa-miR-17-5p;hsa-miR-18a-5p;hsa-miR-19a-3p;hsa-miR-19b-3p;hsa-miR-421;hsa-miR-500a-5p;hsa-miR-501-5p | 11 | ARHGAP5 | Sponge network | -0.596 | 0.00187 | -0.391 | 8.0E-5 | 0.283 |
| 99 | AC005550.3 |
hsa-miR-1301-3p;hsa-miR-132-3p;hsa-miR-17-5p;hsa-miR-188-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-212-3p;hsa-miR-221-3p;hsa-miR-222-3p;hsa-miR-629-3p | 10 | PIK3R1 | Sponge network | -2.571 | 0.00132 | -0.892 | 0 | 0.281 |
| 100 | RP11-7F17.3 | hsa-miR-103a-3p;hsa-miR-106b-5p;hsa-miR-1301-3p;hsa-miR-132-3p;hsa-miR-17-5p;hsa-miR-188-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-221-3p;hsa-miR-222-3p;hsa-miR-324-3p | 11 | PIK3R1 | Sponge network | -0.873 | 0.00204 | -0.892 | 0 | 0.271 |
| 101 | SMIM2-AS1 |
hsa-miR-103a-3p;hsa-miR-106b-5p;hsa-miR-1301-3p;hsa-miR-132-3p;hsa-miR-17-5p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-212-3p;hsa-miR-221-3p;hsa-miR-222-3p;hsa-miR-589-3p;hsa-miR-629-3p | 13 | PIK3R1 | Sponge network | -0.66 | 0.00587 | -0.892 | 0 | 0.27 |
| 102 | DANCR | hsa-let-7a-3p;hsa-let-7b-3p;hsa-let-7b-5p;hsa-let-7f-1-3p;hsa-miR-130a-3p;hsa-miR-199a-5p;hsa-miR-22-3p;hsa-miR-27b-3p;hsa-miR-29a-3p;hsa-miR-29c-3p | 10 | CCNA2 | Sponge network | 1.387 | 0 | 3.368 | 0 | 0.269 |
| 103 | RP11-983P16.4 | hsa-let-7a-3p;hsa-let-7b-3p;hsa-let-7b-5p;hsa-let-7f-1-3p;hsa-miR-130a-3p;hsa-miR-22-3p;hsa-miR-27b-3p;hsa-miR-29a-3p;hsa-miR-29b-1-5p;hsa-miR-29b-3p;hsa-miR-29c-3p;hsa-miR-486-5p | 12 | CCNA2 | Sponge network | 0.673 | 0 | 3.368 | 0 | 0.266 |
| 104 | RP11-538D16.2 | hsa-miR-15b-3p;hsa-miR-16-2-3p;hsa-miR-181a-5p;hsa-miR-181b-5p;hsa-miR-19b-1-5p;hsa-miR-200b-3p;hsa-miR-21-5p;hsa-miR-222-3p;hsa-miR-335-3p;hsa-miR-338-5p | 10 | FGF2 | Sponge network | 0.603 | 0.33218 | -1.086 | 0.00032 | 0.263 |
| 105 | AC068282.3 | hsa-let-7a-3p;hsa-let-7b-3p;hsa-let-7b-5p;hsa-let-7f-1-3p;hsa-miR-130a-3p;hsa-miR-22-3p;hsa-miR-27b-3p;hsa-miR-29a-3p;hsa-miR-29c-3p;hsa-miR-486-5p | 10 | CCNA2 | Sponge network | 0.933 | 6.0E-5 | 3.368 | 0 | 0.256 |
| 106 | RP11-685F15.1 | hsa-miR-106b-5p;hsa-miR-130b-3p;hsa-miR-17-5p;hsa-miR-18a-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-301a-3p;hsa-miR-454-3p;hsa-miR-93-5p | 10 | TGFBR2 | Sponge network | -9.951 | 0 | -0.523 | 3.0E-5 | 0.254 |